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Thanks to the development of antiretroviral agents to control HIV replication, HIV infection has turned from a fatal 
disease into a treatable chronic infection. The present work collects the opinions of several experts on the efficacy 
and safety of recently approved second generation of integrase inhibitors and, in particular, on the role of this new 
class of drugs in antiretroviral therapy.
The availability of new therapeutic options represents an opportunity to ameliorate the efficacy of cART in con-
trolling HIV replication also within viral reservoirs. The personalization of the treatment driven mainly by the 
management of comorbidities, HIV-HCV co-infections and aging, will be easier with antiretroviral drugs without 
drug-drug interactions and with a better toxicity and tolerability profile.
Future assessment of economic impact for the introduction of new innovative drugs in the field of antiretroviral 
therapy will likely need some degree of adjustment of the evaluation criteria of costs and benefit which are current-
ly based almost exclusively on morbidity and mortality.
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iNTRODUCTiON
Adriano Lazzarin
After two decades of major achievements in 
HIV/AIDS care the goal of defeating HIV/AIDS 
is at a crucial juncture, both in terms of its im-
mediate trajectory and its sustainability. 
The development of an effective preventive vac-
cine and a cure remain the ultimate goals in the 
HIV field, however, given the current technical 
and scientific challenges, they are now consid-
ered long term objectives in the global health 
and development agendas. 
Therefore, besides placing a sustained long 
term effort in pursuing these objectives, the 
scientific community must focus on the current 
needs in care and treatment of infected people.
In these regard, improvement of the profile of 
tolerability and efficacy of the available antiret-
roviral compounds is of pivotal importance in 
order to guarantee a life-long accessibility to 
the triple drug combinations that constitute 
modern ART to each HIV infected patient. 
New drugs, including the long-acting antiret-
roviral formulations now in clinical develop-
ment, could be considered as potential tools 
only in the frame of a life-long perspective for 
HIV therapy.
The NEXTAIM project is intended to provide 
a state-of-the-art review of the most recent 
therapeutic options, starting from the concept 
that the availability of a considerable number 
of different cART regimens including integrase 
inhibitors, showing superiority of the perfor-
mances in comparison of the current standard 
of care, represents an unmissible opportunity 
to redraw the plan of action of HIV treatment.
Thanks to the considerable efficacy of cART, 
so far enormous gains have been made in 
controlling HIV replication, saving million of 
people from progression of HIV infection and 
AIDS related illness and death. 
Therefore the next aim of antiretroviral thera-
py must be the capitalization of the innovations 
offered by new drugs to increase the efficacy 
in advanced naïve patients and the long term 
control of ongoing HIV replication in chronic 
patients with a reduced risk of toxicity and tol-
erability. In contrast to the current protocols 
for the evaluation of effectiveness of treatment 
options which are mostly based on the perfor-
mances of the drugs in terms of reduction of 
morbidity and mortality, this project under-
lines the importance of an exhaustive evalua-
tion of the actual welfare gain and cost-benefit 
ratios of cART regimens.
NEW OPTiONS FOR PRE - AND 
POST-EXPOSURE PROPHyLAXiS
Vincenzo Puro, Gabriella De Carli
Despite major advances in antiretroviral treat-
ment, each year around 4000 new HIV-1 infec-
tions occur in Italy (Camoni et al. 2014), and 
2 million new HIV-1 infections are estimated 
worldwide (UNAIDS 2013).
To succeed in achieving a significant reduction 
in HIV-1 incidence, the application of multiple 
prevention measures, i.e. combination HIV-1 
prevention, is recommended, including bio-
medical interventions aimed at HIV-1 unin-
fected individuals in which antiretroviral drugs 
(ARVs) are provided as post-exposure (PEP) or 
pre-exposure (PrEP) prophylaxis (Marrazzo et 
al. 2014). In addition, PEP is a well consolidat-
ed measure for healthcare workers reporting 
an at-risk occupational exposure to HIV (Puro 
et al. 2004; Kuhar et al. 2013).
We here describe available findings for the po-
tential role of HIV integrase inhibitors when 
used as PEP and PrEP.
Post-Exposure Prophylaxis
Animal models and observational human stud-
ies have established the biological plausibility 
of preventing HIV acquisition by prior use of 
nucleoside and nucleotide reverse transcrip-
tase inhibitors (NRTI) (Tsai et al. 1995; Cardo 
et al. 1997; Van Rompay et al. 2001), as well 
as protease inhibitors (PI) (Bourry et al. 2009) 
and integrase strand transfer inhibitors (INS-
TI) (Dobard et al. 2014). Occupational guide-
lines were updated by the US Public Health 
Service in 2013, which advocate for using a 
three-drug regimen for 28 days regardless of 
the severity of exposure (Kuhar et al. 2013) pre-
ferring tenofovir disoproxil fumarate (TDF)/ 
emtricitabine (FTC) with raltegravir (RAL) 
based on improved tolerability of these new-
er ARVs. Indeed, previous regimens including 
co-formulated NRTI and PI resulted highly 
affected by adverse events and inability to tol-
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erate the medication currently prescribed: in 
10 PEP studies published since 2001, and in-
cluding also data from the Italian Registry of 
Antiretroviral Post Exposure Prophylaxis up to 
2014, 14% of 3231 treated individuals failed to 
complete the 28-day course because of adverse 
events, compared to 0.8% of 351 receiving 
TDF/FTC and RAL (Table 1). Also switching to 
RAL-based PEP regimen seems to be associat-
ed with a decrease in reported side effects (An-
nandale et al. 2012).
Apart from significantly more favorable tol-
erability, all three drugs in the recommended 
regimen (TDF, FTC and RAL) act before viral 
TABLE 1 - Completion rates of various post exposure prophylaxis regimens over past 10 years. 
(Modified, from Jain S et al., 2014).
Regimen  
(28 days)
Study Enrollment 
(N)
Exposure Interruptions  
due to side 
effects
Completion rate
AZT/3TC+TDF Burty et al., 2010 171 Occupational 
and sexual 
12.9% 81.5%
AZT/3TC+PI 
(mostly NFV)
Rabaud et al., 2001
Mayer et al., 2008
Winston et al., 2005
79
119
225
Occupational 
and sexual
Sexual
Sexual
10.1%
N.R.
5.8%
64.5% (76% of whom 
with side effects)
38.8%
68%
AZT/3TC+
FPV/RTV
Burty et al., 2008 46 Occupational 
and sexual 
13.0% 47.8% (54.5% of whom
with side effects)
AZT/3TC+ATZ 
unboosted
Diaz-Brito et al., 2012 98 Occupational 
and sexual 
17.3% 64.3%
AZT/3TC+
LPV/RTV
Rabaud et al., 2005 
Diaz-Brito et al., 2012
IRAPEP, 2014
121
102
1806
Occupational 
and sexual 
Occupational 
and sexual 
Occupational 
and sexual 
16.5%;
15.7%;
13.6%
64.5% (48.7% of whom 
with side effects)
63.7%
77.4%
TDF/3TC+
ATZ/RTV
Burty et al., 2010 152 Occupational 
and sexual 
14.5% 79.0%
TDF/FTC+
LPV/RTV
Tosini et al., 2010
IRAPEP, 2014
188
639
Occupational 
and sexual 
Occupational 
and sexual 
11.7%;
12.8%
88.3%, (42.2% of whom
with side effects)
76.8%
TDF/FTC+
RAL
Mayer et al., 2012
McAllister et al., 2014
IRAPEP, 2014
100
86
165
Sexual
Sexual (MSM)
Occupational 
and sexual
None
None
1.8%
84%
92% (9% of whom 
with side effects)
84.8% (29% of whom 
with side effects)
AZT: zidovudine; 3TC: lamivudine; TDF: tenofovir; PI: protease inhibitor; NFV: nelfinavir; FPV: fosamprenavir; RTV: ritonavir; ATZ: 
atazanavir; LPV: lopinavir; IRAPEP: Italian Registry of Antiretroviral Post Exposure Prophylaxis; FTC: emtricitabine; RAL: raltegravir; 
MSM: men who have sex with men.
integration with cellular DNA, providing a the-
oretical advantage in preventing establishment 
of HIV infection. This regimen can be given in 
pregnancy (FDA pregnancy category: TDF and 
FTC: class B; RAL: class C). 
Other features that make RAL an attractive 
candidate for PEP are its potency, ease of use 
(low pill burden, small tablets, and dosing in-
dependently of food), short time from admin-
istration to maximum plasma concentration 
(Tmax), and low potential for drug interactions. 
The latter feature is the basis of the recommen-
dation to use RAL in non-occupational PEP 
(NPEP) regimens started after sexual assault, 
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and whenever there is the need for providing 
emergency contraception with levonorgestrel 
(HIV/AIDS Italian Expert Panel 2014). Indeed, 
efavirenz (EFV) and ritonavir-boosted PIs are 
associated with decreased levels of contracep-
tive hormones that could compromise contra-
ceptive effectiveness requiring an increased 
progestin dose (Robinson et al. 2012), while 
RAL is not known to affect the activity of any 
hepatic cytochrome isoenzymes, and a ran-
domized two-arm crossover study failed to 
demonstrate clinically significant interactions 
between RAL and a triphasic combined oral 
contraceptive (Anderson et al. 2011). 
Finally, RAL has a rapid absorption and a fa-
vorable pharmacokinetic profile with a median 
time to peak plasma concentration in healthy 
volunteers ranging from 0.5 to 1.3 h (Iwamoto 
et al. 2008; Brainard et al. 2011). As RAL tar-
gets an earlier stage of the virus life cycle than 
reverse transcriptase inhibitors, it can inhibit 
infection of primary CD4 T cells and macro-
phages when added at later post-infection time 
points, and thus the length of time after expo-
sure to virus in which the drug can still pre-
vent infection may be extended. The resulting, 
several hours’ difference may be critical in the 
context of PEP (Marsden et al. 2012). 
Recently revised PEP guidelines now recom-
mend similar protocols whether exposures 
were occupational or non-occupational, in-
cluding victims of sexual assault. World Health 
Organization (WHO) recommends that a three-
drug low pill burden regimen is preferable, fa-
voring TDF/FTC plus RAL or ritonavir-boosted 
darunavir (DRV/r) (World Health Organization 
2014), while the New York State Department 
of Health AIDS Institute’s Medical Care Cri-
teria Committee now recommends TDF/FTC 
plus either RAL or dolutegravir (DTG) as the 
preferred initial PEP regimen because of its 
excellent tolerability, proven potency in estab-
lished HIV infection, and ease of administra-
tion (NYSDOH 2014). 
DTG has been more recently approved, and 
earlier studies have demonstrated that it is 
well tolerated and has a much higher barrier 
to resistance than RAL (Hightower et al. 2011; 
Kobayashi et al. 2011), a characteristic which 
would be ideal for high-risk exposures to high-
ly treatment-experienced individuals. In ad-
dition, it can be administered once daily and 
does not require metabolic boosting. A clinical 
trial (NCT02211690) to assess tolerability of, 
and adherence to, DTG with TDF/FTC for HIV 
NPEP, is currently recruiting participants. 
A recent review discussing NPEP trial data and 
management in details (Jain and Mayer 2014), 
suggests that several newer agents, such as the 
integrase strand inhibitors elvitegravir (EVG) 
and DTG, may be useful for PEP when com-
bined with TDF/FTC, but require further study. 
Tolerability studies in HIV-1 uninfected indi-
viduals and long-term clinical experience are 
needed to guide whether these agents or other 
new compounds should be considered for rou-
tine use in NPEP.
Pre-Exposure prophylaxis
Clinical trials of oral PrEP have focused test-
ing on regimens of TDF with or without FTC. 
However, TDF may be associated with toxici-
ties (renal, bone) and FTC may select for drug 
resistance. Moreover, effectiveness is limited by 
low adherence (McMahon et al., 2014). Thus, 
further agents that might serve as alternatives 
to TDF/FTC for HIV-1 prevention are needed. 
ARV drug formulations that require infrequent 
dosing may increase adherence and thus PrEP 
effectiveness.
Optimal PrEP agent(s), as defined by the Divi-
sion of AIDS of the NIAID-NIH, would be safe 
and tolerable, penetrate and protect against 
HIV-1 infection in target tissues, be long-last-
ing with convenient dosing, have a unique re-
sistance profile or a high barrier to resistance, 
have few or no drug-drug interactions, and be 
affordable, easy to use and implement. In addi-
tion, antiretrovirals that are not used common-
ly for HIV-1 treatment would be more attrac-
tive for use as PrEP agents.
In this regard, RAL is generally safe and well 
tolerated, and has few drug-drug interactions; 
its concentrations in vaginal secretions ap-
proximate those in blood, with a half-life about 
twice as long, while in gut-associated lymphoid 
tissue these are 1,5-7 fold higher (Jones et al., 
2009; Patterson et al., 2012); and it has been as-
sessed in a humanized mouse model, demon-
strating efficacy as PrEP (Neff et al., 2010). On 
the other side, it requires twice-daily dosing, 
has a low genetic barrier to resistance, and is 
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used commonly in HIV-1 treatment regimens. 
Due to these limitations, no current clinical 
studies of RAL PrEP are planned (Abraham 
and Gulick 2012).
A new, long-acting, investigational HIV-1 inte-
grase inhibitor, Cabotegravir (GSK1265744) is 
in Phase II clinical development and seems a 
promising drug although integrase inhibitors 
are used commonly in HIV treatment. Cabo-
tegravir is an INSTI and structural analogue 
of dolutegravir with potent anti-HIV-1 activi-
ty, a half-life of about 40 h when dosed oral-
ly, and a low propensity for drug interactions 
(Ford et al., 2013). Monthly injections of the 
experimental drug, Cabotegravir LA, at plasma 
concentrations achievable with quarterly in-
jections in humans, protected all six macaques 
from repeated attempts to infect the animals 
with intravaginal inoculations of SHIV twice a 
week for up to 11 weeks. (Radzio et al., 2015). 
In a second study, where depot medroxypro-
gesterone acetate, which promotes viral trans-
mission vaginally, was added, GSK744 LA 
treatment protected six of eight female rhesus 
macaques against three high-dose SHIV chal-
lenges (Andrews et al., 2015). 
In both studies, all controls receiving placebo 
were infected. These data support advance-
ment of GSK744 LA as a potential PrEP can-
didate for women. Such a long-lasting drug 
would indeed help overcome one of the major 
problems with current medications that at-
tempt to protect against HIV-1 infection - the 
ability of people to take their medication on a 
daily basis. A Phase III clinical trial program is 
expected to be launched soon.
Conclusions
For both PEP and PrEP, the ideal ARV should 
prevent the infection of cells when exposed to 
HIV-1, or at least abort the virus replication cy-
cle acting before viral integration with cellular 
DNA, providing a theoretical advantage in pre-
venting establishment of HIV-1 infection rath-
er than limiting infection.
Before integration, the HIV-1 genome is labile 
and decays with a half-life of approximately 1 
day (Zhou et al., 2005), while once it has inte-
grated, it can persist for the life of the infected 
cell (Finzi et al., 1999). Therefore, the best op-
portunity for preventing a persistent infection 
is to abort the replication cycle of HIV-1 before 
it can integrate (Marsden et al., 2012).
For both PEP and PrEP, other drug character-
istics critical when selecting the appropriate 
ARVs are safety, tolerability, adequate penetra-
tion into target tissues, convenient dosing, and 
few potential drug-drug interactions. Safety is 
the most important quality of a PEP and PrEP 
agent, due to the fact that these preventive 
drugs are being targeted for use by HIV-1 un-
infected individuals, while tolerability strong-
ly impacts on the individual adherence to the 
proposed regimen, therefore affecting its po-
tential efficacy. 
As for PEP, currently available integrase in-
hibitors have many of the characteristics of an 
ideal agent and are currently recommended in 
first line regimens, while for PrEP, new agents 
in this class are being developed which show 
promising results and might represent a new 
option in HIV prevention.
EViDENCES SUPPORTiNG THE 
USE OF iNTEGRASE iNHiBiTORS 
FOR EARLy TREATmENT iN PHi
Giuseppe Tambussi, Silvia Nozza
The role of combination antiretroviral therapy 
(cART) in the management of Primary HIV-1 
infection (PHI) remains controversial; current 
guidelines strongly recommend ART in symp-
tomatic patients (HIV/AIDS Italian Expert Pan-
el 2014). They generally are classified as Fiebig 
III-V stages.
In chronic HIV-1 infection cART reduces mor-
tality and morbidity, but these data were non 
clear in PHI, due to small and proof of concept 
studies. The SPARTAC study is the first mul-
ticentric randomised trial that enrolled 366 
participants; it demonstrated that a 48-week 
course of cART in patients with PHI delayed 
disease progression (Spartac Trial Investigators 
et al., 2013). cART cannot cure the infection 
and stopping cART has been associated with 
risk (Saez-Cirion et al., 2013). However, 14 HIV-
1 patients has been identificated as post treat-
ment controllers (PTCs), the viremia remained 
controlled for several years after the interrup-
tion of prolonged cART initiated during the 
primary infection (Strategies for Management 
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of Antiretroviral Therapy Study Group et al., 
2006). Moreover, the incidence of viral control 
after the interruption of early antiretroviral 
therapy was higher among the PTCs than has 
been reported for spontaneous control. These 
results show that early and prolonged cART 
may allow some individuals with a rather unfa-
vorable background to achieve long-term infec-
tion control and may have important implica-
tions in the search for a functional HIV-1 cure. 
There is not a recommended regimen in PHI 
treatment, but PIs based therapy were general-
ly preferred due to higher genetic barrier. How-
ever, the implication of HIV-1 DNA in disease 
progression and viremia post treatment control 
made INSTIs an attractive option. SPARTAC 
trial explored associations between HIV-1 DNA 
and immunological and virological markers 
of clinical rebound, including viral rebound 
in those interrupting therapy. HIV-1 DNA was 
more predictive of disease progression than 
HIV-1 plasma viral load and, at treatment in-
terruption, predicted time to plasma virus re-
bound. Fast decline of HIV-1 RNA associated 
with INSTIs usage is important in PHI, that 
generally is characterised by high viral load lev-
els, for resolution of symptomatic stage and for 
implications in transmission.
Conclusions
There are not study of triple standard therapy 
with INSTIs and NRTIs in PHI treatment, but 
results in clinical trials in patients’ subset with 
HIV-1 RNA viral load above 100,000 copies/mL 
are good; most important limitation is the re-
sistance test, often not available when therapy 
is started. There are not registered INSTIs mu-
tations in naïve patients, another motivation 
for the use of this class.
immUNOLOGiCAL ASPECTS
Andrea Gori, Stefano Rusconi
The main objective of antiretroviral therapy 
was initially limited to the prevention of the 
clinical manifestations of AIDS, thus reduc-
ing the HIV/AIDS mortality. This objective has 
been largely achieved, due to enormous prog-
ress in the pharmaceutical arena (Guihot et al. 
2010). Nevertheless, it is clear that the man-
agement of HIV-1 infection is rapidly changing 
and the results it is aimed nowadays are very 
different from before. The virologic control of 
HIV-1 cannot be considered the unique scope 
of antiretrovirals with a long-life therapy (Au-
tran et al. 1997). 
The new approach to HIV-1 disease includes 
non-AIDS morbidities, with a particular em-
phasis on cardiovascular pathologies, neuro-
cognitive impairment, bone deterioration, and 
cancer. Despite a long-lasting control of HIV 
replication, we still detect elevated levels of 
inflammation and, less so, T cell immune-ac-
tivation (Tenorio et al. 2014) and these altered 
parameters are somehow connected with the 
lack of immune reconstitution and the onset of 
non-AIDS morbidities. This process resembles 
what is seen in the physiological immunose-
nescence (Deeks 2011). 
Our armamentarium is composed of several 
classes of antiretroviral drugs, so it is funda-
mental to understand the role of these com-
pounds in regulating the immune system, thus 
preventing those pathologies that are related to 
its unbalance.
Pathogenesis of immune-reconstitution: the 
cross-link among HiV-1 disease, CD4 T lym-
phocytes and HiV-1 RNA
The progressive lost of CD4 T lymphocytes is 
one of the peculiar characteristics of HIV-1 dis-
ease. Although HIV-1 is targeted to the destruc-
tion of CD4 T lymphocytes, the pathogenetic 
pathway that causes their decrease is made up 
by a network of complex mechanisms (Gou-
geon and Montagnier 1999; Hunt et al. 2003; 
Bandera et al. 2010). Killing of CD4 T lympho-
cytes is mediated directly by the viral cytopath-
ic effect and indirectly by various actions - e.g. 
apoptosis - that are stimulated by increased 
levels of immune-activation (Gougeon and 
Montagnier 1999; Hunt et al. 2003; Bandera et 
al. 2010). On the other side, the consequent ho-
meostatic activity tries to counteract the HIV-1 
mediated effect via the increased production of 
bone marrow progenitor cells (such as CD34 
cells) and the cellular differentiation in the thy-
mus (Isgro et al. 2008). 
All of this, notwithstanding the fact that these 
two body districts are severely compromised by 
HIV-1 in the early phases of infection, togeth-
er with the gastro-intestinal tract (Brenchley et 
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al. 2004). Thus, HIV-1 is able to compromise 
CD4 T naïve lymphocyte production through 
the interaction in the bone marrow and in the 
thymus, or in what is left behind. As a conse-
quence, the deficit in the turnover of naïve CD4 
T lymphocytes and of mature memory CD4 T 
lymphocytes is accelerated by the antigen-spe-
cific clonal expansion and the antigen-indepen-
dent homeostatic defect. This malevolent net-
work brings to an almost complete deprivation 
of the CD4 T cell compartment, both organic 
and functional.
In the absence of antiretroviral treatment, the 
progression of HIV disease is strictly related 
to HIV-1 RNA levels but its course is a con-
sequence of other surrogate markers, such as 
HIV-1 DNA, residual viremia, and immune-ac-
tivation (Hunt et al. 2003). All these parameters 
have been demonstrated to be connected to the 
mechanisms that are involved in the lack of im-
mune response in HIV-1 infected patients who 
receive antiretrovirals and present an optimal 
virological response.
cART contribution
After starting an antiretroviral combination 
regimen, the usual observation is represented 
by a decrease in HIV-1 viral load and an in-
crease in CD4 T lymphocytes. This last aspect 
is related to the removal of the block that pre-
cludes the immune-reconstitution. These com-
plex mechanisms provide different kinetics ac-
cording to the cell type that is involved. The 
CD4 T cell compartment is going towards an 
immune-reconstitution passing through two 
main stages. The first one, after the cART be-
ginning and the consequent reduction in HIV-1 
viremia, is constituted by a rapid increase of 
memory CD4 T lymphocytes, which is indepen-
dent from a homeostatic mechanism of repop-
ulating naïve CD4 T cells. 
This early phase is mainly caused by redistri-
bution processes from the lymphoid organs 
where cART reduced the load of HIV-1 replica-
tion and thus inflammation. This stage is char-
acterized by a reduction in the pro-inflamma-
tory cytokines and chemokines, such as TNF-a, 
IL-6 e MCP-1. 
At the same time, there is an increase in the 
number of CD8 T lymphocytes, NK cells and 
B cells in the peripheral blood, also reflecting 
a non-specific mechanism of cellular redistri-
bution induced by the reduction of viral repli-
cation. Next, the second phase of immune-re-
constitution that occurs over several years is 
implemented and this the result of the regen-
eration of the population of naïve CD4 T lym-
phocytes, which restores the diversity of the 
T cell receptor (TCR) repertoire. The immune 
processes involving the reconstitution of naïve 
lymphocytes characteristically take place more 
slowly and involve cell phenotypes significantly 
more involved in the functional recovery of the 
correct T cell homeostasis. Of note, the com-
partment of the central memory CD4 T lym-
phocytes, particularly susceptible to HIV-1 in-
fection during the course of the disease, seems 
to play a key role in the successful restoration 
of both numerical and mostly functional mech-
anisms of immune reconstitution after initia-
tion of cART (Autran et al. 1997; Hunt et al. 
2003).
In this regard, there is still some controversy 
on the role of cART for the proper reconstitu-
tion of the damaged CD4 T cell compartment, 
which had been infected with HIV-1. Some 
studies have reported, in some clinical condi-
tions, failure in the reconstitution of CD4 T lym-
phocytes in the long term, showing a plateau 
in the process of immune-reconstitution after 
4-5 years of cART. This phenomenon seems to 
reflect a variety of factors, including age, CD4 
T cell counts before the start of cART (CD4 T 
cell nadir) and intermittent HIV-1 replication. 
It was also demonstrated that hyperactivation 
of CD4 T cell lymphocytes can persist even af-
ter obtaining virologic suppression mediated 
by cART and may have a significant adverse 
effect on the recovery of CD4 T lymphocytes 
during therapy. In fact, despite the drop of vi-
ral replication in plasma, subjects with a mod-
est immune reconstitution maintain high lev-
els of CD4 T lymphocytes activation, which is 
com(Cahn et al. 2013) parable to that observed 
in subjects who do not show viral suppression. 
These data, as well as highlighting the possible 
pathogenic role of immune-activation on the 
recovery of CD4 T lymphocytes, raise the issue 
of the real cause of the persistent lymphocyte 
activation. The residual viral replication, the 
persistent antigenic stimulation mediated by 
microbial translocation, and viral packaging 
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have been proposed as possible mechanisms 
underlying the persistent lymphocyte activa-
tion during cART (Hunt et al. 2003; Marchetti 
et al. 2006; Moore and Keruly 2007; Bandera et 
al. 2010).
Role of integrase inhibitors
The fastest dynamics of virologic suppression 
induced by integrase inhibitors may also affect 
the immune recovery to a higher degree. The 
hypothesis is that integrase inhibitors may ex-
tinguish the kinetics of viral replication faster 
and to a greater extent and are able to impact 
on the pathogenetic mechanisms at the basis 
of the processes of immune reconstitution in 
a more effective than the other antiretrovirals. 
This is particularly interesting in regards to 
the mechanism of T lymphocyte homeostasis, 
which allows a more complete recovery of the 
immune function. 
Integrase inhibitors may be able to interact 
significantly on two essential mechanisms: im-
mune-activation and immune-proliferation, 
as they are closely related to the mechanisms 
underlying the phenomena of immune exhaus-
tion and the depletion of CD4 T lymphocytes 
related to HIV-1 replication. These effects are 
mirrored by the CD4 T lymphocytes gain and 
the improvement in the quality of immune 
system as seen in both naïve and drug-experi-
enced patients (Cahn et al. 2013; Rockstroh et 
al. 2013).
ViROLOGiCAL ASPECTS  
AND RESiSTANCE
Maria Mercedes Santoro, Massimo Clementi, 
Carlo Federico Perno
Resistance profile of iNSTis
NSTIs potently inhibit HIV-1 and HIV-2 repli-
cation by blocking the strand-transfer reaction 
that catalyzes integration of HIV DNA into the 
host genome (Geretti et al., 2012). Despite their 
high potency and tolerability, the first genera-
tion INSTIs RAL and EVG offer a low-to-mod-
erate genetic barrier to resistance, depending 
on the background drug-regimen (Geretti et al., 
2012). 
RAL failure is associated with integrase muta-
tions in at least 3 distinct, but non-exclusive, 
genetic pathways defined by 2 or more mu-
tations including a primary mutation among 
Q148H/K/R, N155H or Y143C/H/R and at least 
one additional minor mutation (Canducci et 
al., 2010). Minor mutations described in the 
Q148H/K/R pathway include L74M, E138A/K, 
or G140S. The most common pathway is 
Q148H+G140S, which also confers the greatest 
loss of drug susceptibility. Minor mutations de-
scribed in the N155H pathway include L74M, 
E92Q, T97A, Y143H, G163K/R, V151I, or 
D232N (Wensing et al., 2014). N155H mutants 
tend to predominate early in the course of RAL 
failure, but are gradually replaced by viruses 
with higher resistance, often bearing muta-
tions Q140S+Q148H/K/R, with continuing RAL 
treatment (Wensing et al., 2014). Y143C/R is of-
ten associated with the polymorphic mutation 
T97A. This combination strongly reduces the 
susceptibility to RAL and rescues the catalytic 
defect due to the Y143C/R mutation (Reigadas 
et al., 2011). 
The following EVG mutations have been ob-
served in INSTI-naïve and experienced patients 
in whom therapy is failing: T66A/K/I, E92Q/G, 
T97A, F121Y, S147G, Q148H/K/R, N155H 
(Wensing et al., 2014). In the phase III studies 
GS-US-236-0102, patients failing a first line 
regimen containing EVG/cobicistat (COBI)/
FTC/TDF fixed dose combination, the rate of 
resistance development was 2.9% (White et 
al., 2015). Despite this very low prevalence of 
resistance emerged at failure, in EVG arm all 
patients with primary genotypic resistance-as-
sociated mutations to INSTI (mostly E92Q) 
showed also the M184I/V mutation. Different-
ly, in the EFV arm, even if the prevalence of re-
sistance was slightly higher, only around 30% 
of patients showed resistance to both non-nu-
cleoside reverse transcriptase inhibitors (NNR-
TI) and NRTI class (White et al., 2015). Thus a 
clear linkage of integrase resistance mutations 
and M184V/I was observed in this study as well 
as in other studies evaluating RAL resistance 
such as STARTMRK and QDMRK (Eron et al., 
2011; Rockstroh et al., 2013). 
RAL and EVG share cross-resistance: resistant 
strains emerge rapidly during in vitro passage 
experiments, and in a short-medium period in 
patients experiencing virological failure. For 
this reason, the sequential use of these two IN-
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STIs (in either order) may be problematic. 
Differently, DTG has limited cross-resistance to 
RAL and EVG in vitro, and offers the promise 
of an improved genetic barrier to resistance 
(Geretti et al., 2012). Indeed, this INSTI main-
tains its activity in vitro against viruses with 
Q148 single mutants or against viruses with 
Y143 or N155 signature mutations regardless 
of RAL-associated secondary mutations (Can-
ducci et al., 2011). On the other hand, cross-re-
sistance studies with RAL- and EVG-resistant 
viruses indicate that Q148H and G140S in com-
bination with mutations L74I/M, E92Q, T97A, 
E138A/K, G140A, or N155H are associated 
with 5-fold to 20-fold reduced DTG susceptibil-
ity (Geretti et al., 2012) and reduced virologic 
suppression under DTG treatment (Eron et al., 
2013a; Raffi et al., 2013b; Castagna et al., 2014). 
Indeed, in treatment experienced INSTI-resis-
tant patients, the response rates (both at day 
8-10 and week 24 of DTG-treatment) were 
closely related to the presence of Q148 plus ≥2 
secondary mutations (among L74I, E138A/K/T 
and G140A/C/S) at baseline (Eron et al., 2013a; 
Castagna et al., 2014). These findings suggest 
that in RAL failing subjects, the presence of 
only few and specific INSTI resistance muta-
tions confer reduced susceptibility to DTG. 
Beyond the mutation already associated with 
resistance to first line INSTIs, DTG can select 
the specific R263K mutation with other specific 
mutations such as H51Y, G118R and F121Y in 
vivo and in vitro (Malet et al., 2014; Mesplede 
and Wainberg 2014). However, these mutations 
strongly diminishes both viral replication ca-
pacity as well as the enzymatic activity of the 
integrase, impairing the ability of the viruses 
harbouring these mutations to acquire further 
resistance(Oliveira et al., 2014). 
This phenomenon might explain the fact that 
DTG, when used as part of first-line therapy, is 
the only HIV-1 drug that has not selected for 
resistance mutations in the clinic. Indeed, in 
individuals failing a first line regimen contain-
ing DTG, no INSTI, NRTI or PI mutations have 
been found (Raffi et al., 2013a; Mesplede and 
Wainberg 2014). 
Moreover, in pluri-treated individuals failing 
DTG as first INSTI, the proportion of subjects 
with evidence of INSTI resistance is signifi-
cantly lower if they were treated with DTG (50 
mg once daily, QD) than those failing to RAL 
(400 mg twice daily, BD) (Cahn et al., 2013). 
A potential role of integrase and reverse tran-
scriptase mutations on susceptibility to INSTIs 
was recently described. Indeed, a synergistic 
effect of NNRTI resistance mutation K103N 
or E138K with INSTI resistance mutations 
G140S/Q148H on susceptibility to EFV and/
or RAL was demonstrated (Hu and Kuritzkes 
2014).
Efficacy of iNSTis
A crucial characteristic of the INSTI activity in 
vivo is the prompt virological response. Indeed, 
a rapid virological suppression was observed in 
patients treated with co-formulated EVG/COBI/
FTC/TDF versus co-formulated EFV/FTC/teno-
fovir or co-formulated FTC/TDF and ritona-
vir-boosted atazanavir (ATV/r) (DeJesus et al., 
2012; Sax et al., 2012). Again, in DTG Clinical 
Trial Program, a rapid and significant virolog-
ical suppression has been observed with DTG 
vs DRV/r and EFV (Walmsley et al., 2013; Clo-
tet et al., 2014).Similar results were previously 
reported when RAL was compared with EFV 
(Lennox et al., 2009), and fully confirmed by 
clinical practice. Two recent systematic reviews 
and meta-analysis showed a significant clini-
cal benefit in favour of INSTIs in combination 
with two NRTIs in HIV-1 individuals starting a 
first-line regimen in comparison to other third 
drug classes (Messiaen et al., 2013; Lee et al., 
2014). In particular, the meta-analysis by Lee et 
al., supported the superiority of all 3 INSTIs as 
third drug options compared to NNRTIs (Lee et 
al., 2014). In the ACTG 5257 (aiming to com-
pare the efficacy and safety of three non-nucleo-
side-sparing regimens in US antiretroviral-naïve 
adults with a HIV-1 RNA viral load >1,000 cop-
ies) first-line RAL proved superior to ATV/r or 
DRV/r (all taken with TDF/FTC) after 96 weeks 
of treatment in an endpoint combining virolog-
ic efficacy and safety. Findings from SPRING-2, 
SINGLE and FLAMINGO studies supported the 
use of DTG in adult treatment-naïve HIV-1-in-
fected subjects (Raffi et al., 2013a; Raffi et al., 
2013b; Walmsley et al., 2013; Clotet et al., 2014). 
A non-inferiority of DTG (50 mg QD) to RAL (400 
mg BD) was overall demonstrated both at week 
48 and week 96 (SPRING-2) (Raffi et al., 2013a; 
Raffi et al., 2013b). In particular, a superiority of 
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DTG to RAL at 96 weeks was demonstrated for 
baseline HIV-1 RNA viral load >100,000 copies/
mL. A superiority of DTG plus abacavir (ABC)/
lamivudine (3TC) compared to the single tablet 
regimen EFV/TDF/FTC was demonstrated at 
week 48, 96 and 144 (SINGLE study) (Walmsley 
et al., 2013; Walmsley et al., 2015). A superior-
ity of DTG (50 mg QD) to DRV/r (800/100 mg 
QD) at 48 and 96 weeks of treatment was also 
demonstrated (FLAMINGO study) (Clotet et al., 
2014; Molina et al., 2015). 
Overall, these results imply similar efficacy 
within the INSTI class, a position since adopted 
by the Department of Health and Human Ser-
vices in October 2013 and the International An-
tiviral Society - USA in July 2014, when all three 
INSTIs became listed as ‘Preferred’ options in 
combination with 2 NRTIs (DHHS Panel on 
Antiretroviral Guidelines for Adults and Adoles-
cents 2014; Gunthard et al., 2014).
Novel treatment strategies at first line failure, 
such as the combination of INSTI with a PI 
(sparing the NRTIs) have been also explored. A 
large trial evaluating this concept (NEAT-001) 
showed that RAL boosted DRV is non-inferior 
at week 96 compared to TDF/FTC/DRV/r and 
may represent a treatment option for patients 
with CD4 T cell counts higher than 200 cells/
μL (Raffi et al., 2014). However, this RAL plus 
DRV/r was less effective in patients starting with 
a high baseline HIV-1 RNA viral load (>100,000 
copies/mL). 
Use of INSTI is beneficial even in treatment-ex-
perienced patients with virological failure (Mes-
siaen et al., 2013). In treatment-experienced IN-
STI-naïve patients, EVG QD was non-inferior to 
RAL BD and showed durable long-term efficacy 
(Elion et al., 2013), while a superiority of DTG 
to RAL was demonstrated at week 48 (Cahn et 
al., 2013). In highly treatment-experienced pa-
tients harbouring RAL- and/or EVG resistant 
viruses, the administration of DTG 50 mg BD is 
effective; a reduction of response is associated 
with the baseline presence of Q148 plus at least 
two resistance associated mutations (Castagna 
et al., 2014; Akil et al., 2015). 
Recent evidence demonstrated that EVG, COBI, 
FTC in combination with 2 NRTIs might be a 
suitable alternative in virologically suppressed 
patients under a NNRTI based regimen (Pozniak 
et al., 2014). However, in successfully treat-
ed patients with a history of therapy failure, 
switching a high genetic barrier drug towards 
an INSTI is not supported by the meta-analyses 
(Messiaen et al., 2013). The results indicate that 
when switching virologically suppressed pa-
tients, individual patient management is needed 
to assess history of treatment failure, available 
resistance profiles and duration of the current 
suppressive regimens in order to perform a safe 
switch.
Conclusions
RAL, EVG and DTG appear equivalent in re-
gard to their efficacy in therapy of both naïve 
and treatment-experienced HIV-1 individuals. 
A recently published network meta-analysis, 
that can provide estimates of relative efficacy 
for treatments not directly studied in head to-
head randomized controlled trials, suggests 
that DTG is also favorable or comparable to 
other commonly used third agents (ATV/r, 
LPV/r, RPV, and EVG/c) (Patel et al., 2014). 
However, substantial differences are found in 
regard to HIV-1 drug resistance. Indeed, be-
cause of the low/moderate genetic barrier of 
RAL and EVG, to avoid the resistance develop-
ment, particular attention should be deserved 
on adherence levels and on background drugs 
used in both cART-naïve and cART-experienced 
patients treated with these INSTIs. The broad 
cross-resistance profile between RAL and EVG 
precludes their sequential use in individuals 
failing either of them. 
Differently, in patients who have previously 
failed to RAL or EVG, even though the pres-
ence of Q148 with at least two additional INS-
TI mutations can decrease their response rate, 
DTG BD administration may warrant a resid-
ual efficacy. Moreover, the emergence of novel 
resistance under DTG treatment is a rare event 
that select viruses less prone to accumulate 
further resistance because of their low replica-
tion capacity. 
Indeed, in treatment naïve patients, DTG is the 
only antiretroviral for which no emergent re-
sistance has been detected. These unique prop-
erties of DTG may have relevance for public 
health strategies aimed at limiting or stopping 
the spread of HIV-1.
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EViDENCES SUPPORTiNG THE 
USE OF iNTEGRASE iNHiBiTORS 
FOR FiRST LiNE THERAPy
Antonella d’Arminio Monforte, 
Franco Maggiolo
The beginning of the cART era traces back to 
1996 in Vancouver, where the two events which 
would have constituted the first two milestones 
of HIV therapy took place. 
The first milestone was the the publication of 
the clinical studies involving protease inhibi-
tors, whereas the second was the introduction 
of a quantitative method to measure plasma 
HIV-RNA, the diagnostic tool which allowed to 
shorten the time necessary for drug develop-
ment of the future ARVs. 
Despite having a precise date of birth, cART 
evolved gradually, led by a progressive optimiza-
tion of the overall aims, endpoints, therapeutic 
regimens, and patient management. 
The current aim of cART is extending the life 
span of the patients while at the same time pre-
serving the quality of their lifes, i.e. a life with-
out disease as well as without therapy side ef-
fects.
So far, cART is made by the combination of three 
ARVs, although this concept is currently debat-
ed. Despite little changes in the cART setup over 
the last two decades, significant progresses have 
been made in drug formulation, delivery and 
combination. Initially, the regimens were ex-
tremely demanding for the patients who needed 
to take up to 12 tablets per day. The request for 
multiple doses was mostly related to the short 
plasmatic half life of the majority of the mole-
cules. It was also for this reason that high dos-
es of ARVs were administered to the patients, 
increasing the likelihood of adverse events. To 
limit the onset of adverse effects and maximize 
the absorption of the active compounds, dietary 
restrictions and limitations to the intake of food 
and liquids were often mandatory. Over the 
time, the number of tablets, the number of daily 
doses as well as dietary restrictions have been 
significantly reduced. Among all the factors de-
termining this evolution, three have played a 
major role. First, the introduction of new mol-
ecules and new classes of drugs, whose devel-
opment was specifically targeted at improving 
farmacokinetic properties and absorption rate 
and at extending the half-lives of the active mol-
ecules. This was the case for the NNRTIs, which 
were introduced at the beginning of the cART 
era, and for the most recent PIs: Second, the 
intuition that modulation of drug metabolism 
could improve efficacy, tolerability and overall 
convenience of specific ARVs. Based on this no-
tion, new drugs were developed to be used as 
boosters, i.e. drugs which influence the metab-
olism and excretion of other farmaceutic com-
pounds by regulating the hepatic microsomal 
system. Finally, the commitment of the pharma-
ceutical industry which led to a constant evo-
lution in terms of pharmacological techniques. 
All together, these processes allowed to evolve 
new therapies with increasing efficacy, as 
demonstrated by the increase in the number 
of positive outcomes in clinical trials over the 
time. The initial goal of therapy optimization 
has been improvement of drug efficacy, howev-
er, in a later time the focus has been moved to 
the parallel improvement of tolerability since 
coupling these two characteristics guarantees 
better clinical outcomes. Integrase inhibitors, 
the most recent class of drugs introduced in 
HIV therapy, can be considered an example of 
this new line in drug development as shown by 
the recent drug registration studies.
Currently two new molecules belonging to 
INSTI class have been licensed: EVG (as sin-
gle tablet regimen contained EVG/COBI/FTC/
TDF) and DTG. The following paragraphs will 
describe the clinical trials which supported the 
registration of these new drugs.
The study 103 (DeJesus et al., 2012) is a random-
ized double blind phase III clinical trial (1:1), 
aimed at evaluating efficacy, safety and toler-
ability of EVG 150 mg/COBI 150 mg/FTC 200 
mg/TDF 300 mg (n=353) compared with ATV/r 
(300 mg ATV, 100 mg RTV) combined with FTC 
200 mg/TDF 300 mg (n=355) in adult patients 
naive to therapy with HIV RNA >5000 copies/
mL. The primary endpoint of the Study 103 was 
suppression of viral replication (HIV RNA <50 
copies/mL) at 48 weeks of treatment, according 
to the FDA approved snapshot algorithm.
At baseline, average HIV RNA and CD4 T cell 
count were 4.88 log10 copies/mL and 364 cells/ 
μL, respectively, in the EVG arm, whereas pa-
tients included in the ATV/r arm showed 4.86 
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log10 copies/mL HIV RNA and a CD4 T cell 
count of 375 cells/μL. Considering both arms 
together, 41% of the patients showed baseline 
plasma HIV RNA above 100000 copies/mL, and 
13% had a baseline CD4 T cell count equal or 
lower than 200 cells/μL. CD4 T cell counts in-
creased at similar rates for both treatment arms 
with an average increase of 207 cells/μL in the 
EVG arm and of 211 cells/μL in the ATV/r arm. 
The rate of virological failure was 5% for both 
therapeutic schemes. Common adverse events 
(at least 10% of the patients) for both treat-
ment arms were: diarrhoea, nausea, upper re-
spiratory tract infections, headache, fatigue and 
ocular jaundice. Common adverse events were 
reported at similar rates between the two treat-
ment arms, with the exception of scleral jaun-
dice which was more frequently observed in the 
EVG arm compared to the ATV/r arm (1% and 
14%, respectively).
The Study 102 (Sax et al., 2012) is a a random-
ized double blind phase III clinical trial (1:1), 
aimed at evaluating efficacy, safety and tolera-
bility of the combination EVG/COBI/FTC/TDF 
(n=348) vs EFV 600 mg/FTC 200 mg/TDF 300 
mg (n=352). Enrolled patients were adults naive 
to treatment with a plasma HIV RNA concen-
tration of 5000 copies/mL or more. The primary 
endpoint of the Study 102 was suppression of 
viral replication (HIV RNA <50 copies/mL) at 48 
weeks of treatment, according to the FDA ap-
proved snapshot algorithm.
At baseline, patients included in the EVG arm 
had an average plasma HIV-1 RNA of 4.75 log10 
copies/mL and an average CD4 T cell count of 
391 cells/μL. In EFV treated group, average 
plasma HIV-1 RNA was 4.78 copies/mL and av-
erage CD4 T cell count was 382 cells/μL. Overall 
33% of patients had plasma HIV-1 RNA above 
100.000 copies/mL, and 13% of patients had a 
CD4 T cell count equal or below 200 cells/μL. 
The overall virological failure rate was compa-
rable (7%) in the two arms of treatment. Among 
the patients with plasma HIV RNA above 
100.000 copies/mL at baseline, 84% of patients 
in the EVG arm and 82% of patients in the EFV 
arm achieved virological suppression. The av-
erage CD4 T cell count increase was 239 cells/
μL among EVG treated patients and 206 cell/μL 
among EFV treated patients (p>0,009). 
During the study, 4% of patients included in 
the EVG arm and 5% of patients included in 
the EFV arm stopped treatment due to adverse 
events. The adverse events which were more 
frequently reported, for both treatment arms, 
were: diarrhoea, nausea, and rash. EVG treated 
patients reported less frequently neuropsychiat-
ric adverse effects including abnormal dreams 
(15% of the EVG treated patients vs 27% of the 
EFV treated patients), dizziness (7% vs 24%), 
and insomnia (9% vs 14%). The average in-
crease in total cholesterol and LDL cholesterol 
was lower among EVG treated patients (+10 
mg/dl total cholesterol; +10 mg/dl LDL choles-
terol) compared to EFV treated patients (+19 
mg/dl total cholesterol e +17 mg/dl LDL choles-
terol) (p=0.001). The average increase in serum 
creatinine levels was 0,14 mg/dl in the EVG arm 
e a 0,01 mg/dl in the EFV arm.
The clinical evaluation of the more recent inte-
grase inhibitor, DTG, included a comparison of 
the new drug with existing drug combinations 
including RAL or with EFV and DRV based 
drug regimens.
The SPRING study (Raffi et al., 2013a) is a 
non-inferiority study, aimed at comparing the 
efficacy and safety of a single daily 50 mg dose 
of DTG with 400 mg twice daily dose of RAL, 
both administered in combination with two 
NRTIs. The 411 HIV patients naïve to treatment 
included in the study were randomly assigned 
to one of the two arms. The primary endpoint 
was the proportion of participants with HIV-1 
RNA less than 50 copies per mL at 48 weeks 
according to the FDA approved snapshot algo-
rithm. Primary endpoint, i.e. non inferiority of 
DTG compared to RAL, has been met. After 48 
weeks of treatment 88% and 85% of patients 
showed complete virological suppression in the 
DTG and RAL arm, respectively. At week 96, 
81% patients in the DTG group and 76% in the 
RAL group had HIV-1 RNA less than 50 copies 
per mL confirming non-inferiority (Raffi et al., 
2013a) 
Tolerability was similar between treatment 
groups, with few adverse events leading to 
discontinuation (2% in each group). Approxi-
mately 10% of study participants in each group 
reported nausea attributable to the treatment; 
whereas other adverse events were reported in 
less than 5% of the patients enrolled in both 
treatment arms.
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SINGLE is a double blind, multicenter random-
ized clinical trial comparing the safety and effi-
cacy of DTG at a dose of 50 mg plus ABC/3TC 
once daily with the fixed dose combination 
EFV/tenofovir/emtricitabine (Walmsley et al., 
2013). Treatments were administered for 48 
weeks in adult HIV-1 infected patients naïve 
to treatment. 833 patients were enrolled and 
randomly assigned to treatment, (414 treated 
with DTG based combination and 419 with con-
trol regimen). The median age of the patients 
enrolled in the study was 35 years, majority 
were man (84%), white, with a median CD4 T 
cell count was 338 cells/μL. After 48 weeks of 
treatment, 364 (88%) of patients in the DTG 
group achieved virological suppression (prima-
ry endpoint of the study according to the FDA 
Snapshot algorithm) compared to 338 (81%) 
in the control group meeting the criterion for 
DTG based combination superiority (p=0.003). 
No significant differences in virological re-
sponse were observed between the two regi-
mens. Moreover, virological response remained 
similar across subgroups after stratification for 
baseline viral load (threshold 100.000 copies/
mL plasma HIV-1 RNA) and CD4 T cell count 
(threshold 200 cells/μL). Within the subgroup 
with a viremia below 100.000 copies/mL, 90% 
of patients in the DTG arm achieved virologi-
cal suppression compared with 83% of patients 
in the EFV arm, whereas within the subgroup 
with a viremia above 100.000 copies/mL the 
percentage of patients achieving plasma HIV-1 
RNA load <50 was 83% and 76% in the DTG and 
EFV arm, respectively. Overall patients showed 
a more favourable response in the DTG group 
compared with the EFV group, both within the 
subgroup with a baseline CD4 T cell count high-
er than 200/μL (89% vs 81%) as well as within 
the subgroup with a baseline CD 4 T cells count 
lower than 200 cells/μL (79% vs 77%), although 
these differences did not reach the level of sta-
tistical significance. Moreover, DTG treated pa-
tients achieved virological suppression more 
rapidly than EFV treated patients (28 days vs 84 
days) and the regimen was associated to a sig-
nificantly higher CD4 T cell increase (267 cells/
μL in the DTG arm vs 208 cells/μL in the EFV 
arm; p<0.001).
Adverse events rate was slightly different be-
tween treatment groups, abnormal dreams, 
rash and dizziness were more common in the 
EFV group, whereas insomnia was reported 
more frequently among participants included 
in the DTG group. The number of patients who 
discontinued therapy owing to adverse events 
was lower in the DTG group than in the EFV 
group (10/414 patients [2%] in the DTG arm 
vs 42/419 [10%] in the EFV arm); of note, the 
higher tolerability of the DTG regimen contrib-
uted to its more favourable outcome that was 
significantly confirmed at week 144 where 71% 
of patients in DTG regimen vs 63% in EFV regi-
men maintained viral load suppression (p=0.01) 
(Walmsley et al., 2015).
FLAMINGO (Clotet et al., 2014; Molina et al., 
2014b) is a randomized study, comparing effica-
cy and tolerability of DTG or DRV/r combined 
with investigator-selected backbone NRTIs. 
HIV-1-positive naïve to antiretroviral therapy 
adults with HIV-1 RNA ≥1000 copies/mL and 
no evidence of viral resistance were enrolled in 
the study. Participants were stratified according 
to plasma HIV-1 RNA levels (100,000 copies/
mL). The primary endpoint was the proportion 
of patients achieving HIV-1 RNA lower than 50 
copies/mL (FDA snapshot and a non inferiori-
ty margin of -12%) by week 48. A total of 488 
adults were randomized among the two groups, 
243 in the DTG arm and 245 in the DRV/r arm. 
Of them, 86% and 79% completed the 96 weeks 
of treatment in the DTG group and DRV/r 
group, respectively. 7% of patients treated with 
DTG and 12% of patients treated with DRV/r 
discontinued therapy before reaching 48 weeks. 
Snapshot analysis at 48 and 96 weeks showed a 
significant virological response in favour of DTG 
arm compared with the DRV/r arm (90% vs 83% 
[p=0.025] at week 48; 80% vs 68% [p=0.002] at 
week 96) (Clotet et al., 2014; Molina et al., 2015)
PIs. This difference was maintained across HIV-
RNA subgroups and was independent of the 
backbone NRTIs (ABC/3TC or TDF/FTC). 
Less than 1% of the patients included in the 
study reported sever adverse events. Of note, 
levels of LDL cholesterol were higher among 
participants receiving DRV/r, whereas serum 
creatinine levels were higher in the DTG arm. 
None of the patients experiencing virological 
failure had treatment-related resistance to study 
drugs. 
Overall, new INSTIs recently introduced in clini-
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cal practice proved to be efficient in suppressing 
viral load in naive patients, supporting their use 
in patients with high levels of HIV-1 replication. 
Moreover, due to the rapidity in inducing viro-
logical response, these new drugs might be par-
ticularly useful in patients identified at serocon-
version. Finally, new INSTIs were well tolerated 
and showed no relevant pharmacological inter-
actions supporting their use in patients under 
treatment for HIV-1 associated comorbidities. 
Taken together, these observations, promote the 
use of INSTIs as a component of first line cART. 
Given the simplicity and convenience of current 
cART regimens (1 or 2 pills/day) the inclusion 
of INSTIs appears to be a feasible resource for 
treatment of patients naive to antiretroviral 
therapy. Moreover, in the case of DTG clinical 
trials, no mutations have been reported, neither 
class specific nor involving other drugs included 
in the regimes. This makes DTG a valid alterna-
tive to regimens including PIs, in particular in 
subjects with high viremia. Given the absence of 
cross resistance between PIs and both INSTIs as 
well as NNRTIs, PIs could be used as a second 
line therapy in patients who fail the treatment 
with INSTIs and NNRTI. 
ROLE OF iNTEGRASE iNHiBiTORS 
iN THE mANAGEmENT OF 
ViROLOGiCAL FAiLURE
Antonella Castagna, Andrea De Luca
In recent years, thanks to the improved effica-
cy of current antiretroviral treatment regimens, 
virological failures occur less frequently in clin-
ical practice. 
However virological failures may sill occur in 
patients treated with different lines of antiret-
roviral therapy and different combinations of 
drug classes.
The use of integrase inhibitors after 
virological failure in patients naïve 
to integrase inhibitors
Several seminal studies have analyzed the role 
of the integrase inhibitors in this particular set-
ting (Table 2). The Benchmrk studies were two 
identical Phase 3 randomized trials comparing 
the efficacy of RAL 400 mg bid versus placebo 
in addition to an optimized background thera-
py (OBT) in 699 patients with documented re-
sistance to at least one drug in each of three 
historical classes of antiretroviral drugs. 
TABLE 2 - Efficacy of integrase inhibitors (INI)-based regimens in treatment failing INI-naïve individuals RCT, 
randomized controlled trial; RTG, raltegravir; EVG, elvitegravir; DTG, dolutegravir; OBT, 
optimized background therapy; VL, viral load.
Study Type INI
type
Accompanying
drugs
Number 48 weeks
<50 cp/mL
Longer term
virologic
responses
Reference
Benchmrk RCT RTG OBT 462 62.1% 156w 51%
VL<50
(Steigbigel et al. 2010; 
Eron et al. 2013)
Imaz Prospective
single arm
RTG DRV/r, ETV 32 94%
(24w)
- (Imaz et al. 2009)
TRIO Prospective
single arm
RTG DRV/r, ETV+
OBT
103 86% 96w 88%
VL<50
(Yazdanpanah et al. 
2009)
145 RCT RTG PI/r + 3rd 
agent
351 58% 96w 45%
VL<50
(Elion et al. 2013)
145 RCT EVG PI/r + 3rd 
agent
351 59% 96w 47.6%
VL<50
(Elion et al. 2013)
Nozza Prospective
single arm
RTG MVC, ETV 28 92%
(OT)
4 years
96% VL<50
(Nozza et al. 2010)
Capetti Retrospective RTG Any 333 4-years
77% VL<50
(Capetti et al. 2014)
SAILING RCT RTG OBT 361 64% (Cahn et al. 2011)
SAILING RCT DTG OBT 354 71% (Cahn et al. 2011)
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The OBT was decided based on the genotypic 
resistance results and DRV at a dose of 600 mg 
bid with ritonavir was permitted. At 48 weeks, 
in the combined analysis of the two studies, 
62.1% of patients on RAL as compared with 
32.9% on placebo obtained virological success 
(Steigbigel et al. 2008). 
Results could be observed throughout the whole 
range of efficacy of the OBT, estimated based 
on the genotypic susceptibility score (GSS, i.e. 
the number of active drugs based on the inter-
pretation of the results of resistance genotyping 
(Cooper et al. 2008)). In particular, HIV-1 RNA 
<50 copies/mL was achieved at 48 weeks with 
an OBT with a GSS=0 in 45% or RAL and 3% 
of placebo recipients, showing a high efficacy of 
RAL even in the context of a functional mono-
therapy. However the best efficacy results were 
obtained when RAL could be supported by ac-
tive and potent companion drugs. Indeed, with 
an OBT GSS=2 77% of RAL recipients (versus 
62% of placebo) achieved virological suppres-
sion. Moreover, in patients who were using en-
fuvirtide (ENF) or DRV for the first time, HIV-
1 RNA <50 copies/mL was achieved in 89% of 
RAL recipients and 68% of placebo recipients. 
At 48 weeks, genotypic resistance mutations to 
RAL were selected in 68% of patients with vi-
rological failure: 75% of these had two or more 
resistance-associated mutations.
Results of the studies were confirmed in the long 
term by a follow-up of 5 years, after the studies 
were unblinded at 3 years and all patients were 
offered to continue open-label RAL (Eron et al. 
2013b). The studies demonstrated the long term 
efficacy on integrase inhibitors as a new drug 
class in this setting and the good tolerability 
profile of RAL, even in the long term.
RAL was also studied in combination with 
DRV/r and etravirine (ETR) in two independent 
non-controlled studies in patients with multi-
drug resistant virus (Imaz et al. 2009).
In the first study, 32 DRV- and integrase inhib-
itors-naïve patients with 3-class resistant vi-
rus were enrolled. At week 24, 94% of patients 
achieved HIV1-RNA less than 50 copies/mL. In 
the second trial 103 patients who were naïve to 
the three drugs and had a history of virologic 
failure with NNRTI, > or =3 primary PI and 
NRTI mutations, and < or =3 DRV and NNRTI 
mutations. In addition 87% of patients received 
OBT that included NRTIs or ENF. At week 48, 
86% had an HIV RNA level <50 copies/mL. 
Only 1 patient discontinued the investigational 
antiretroviral regimen, because of an adverse 
event (Yazdanpanah et al. 2009). At week 96, 
88% achieved durable virologic response (<50 
copies/mL). 
RAL was also studied in a PI-sparing, NR-
TI-sparing regimen in 28 triple-class experi-
enced HIV-1-infected patients harbouring R5 
virus, who received maraviroc (MVC), RAL and 
ETR (Nozza et al. 2010). By on-treatment analy-
sis, 26 (92%) had less than 50 copies HIV-RNA/
mL at week 48. The median 48 week increase 
in CD4 T cell counts was 267 cells/ml. The regi-
men was well tolerated and its efficacy was con-
firmed in the long term. 
In a cohort of 333 ART-failing patients initiat-
ing RAL in the clinical practice, 77% of patients 
had undetectable viral load at 4 years based 
on an intention to treat analysis (Capetti et al. 
2014), but only 32 patients (9.6%) had true viral 
failure.
EVG once daily was compared to RAL twice 
daily in a 96-week, double-blind, randomized 
phase 3 study, in 702 treatment-experienced 
adults receiving a fully active, ritonavir-boost-
ed PI plus a third agent (Elion et al. 2013). The 
proportion of subjects randomized to EVG that 
achieved and maintained HIV-1 RNA <50 cop-
ies/mL through week 96 was 47.6% compared 
with 45.0% for RAL. Both regimens were well 
tolerated, with comparable rates of adverse 
events. 
Finally, DTG 50 mg once daily was compared 
to RAL 400 mg twice daily in a 48 week, phase 
3, randomised, double-blind, non-inferiority 
study. 715 viremic patients with resistance to 
two or more classes of antiretrovirals, with 1-2 
fully active background antiretrovirals were 
randomized 1:1 to receive one of the two inte-
grase inhibitors (Cahn et al. 2013). At week 48, 
71% patients on DTG had HIV-1 RNA < 50 cop-
ies/mL versus 64% on RAL: superiority of DTG 
versus RAL was then concluded. 
Significantly fewer patients had virological 
failure with treatment-emergent integrase-in-
hibitor resistance on DTG (4 vs 17 patients). 
Adverse event frequencies were similar across 
groups, including safety events leading to dis-
continuation.
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Use of DTG in failing HiV infected subjects 
with genotipic evidence of iNis resistance
Resistance to INSTIs is observed with increas-
ing frequency in treatment-failing subjects 
both in America and in Europe. Results from 
specimens sent for clinical decision making to 
the referral US laboratory over a 4 year peri-
od (2009-2012) indicated that among 3294 se-
quences from 3012 patients, 471 patients had 
viruses with ≥1 RAL or EVG resistance muta-
tion (15.6%); Q148 and N155 pathways were 
equally represented, Q148 rarely occurred 
without accessory mutations. 
High-level DTG resistance was predicted in 12% 
of patients with RAL- or EVG-resistant viruses 
(Hurt et al. 2014). In Brazil, analysis of blood 
samples from 92 HIV-infected individuals with 
confirmed virological failure using RAL with 
optimized background showed that 32 of them 
(35%) showed resistance to DTG, in most cases 
associated with the combination of Q148H/R/K 
with G140S/A mutations (Cavalcanti Jde et al. 
2015). 
In France, among 502 treatment-experienced 
patients failing a RAL- containing regimen 
the most frequent mutations observed were 
N155H/S (19.1%), Q148G/H/K/R (15.4%) and 
Y143C/G/H/R/S (6.7%). At RAL failure, virus-
es were considered as fully susceptible to all 
INSTIs in 61.0% of cases, whilst 38.6% were 
considered as resistant to RAL, 34.9% to EVG 
and 13.9% to DTG (Fourati et al. 2015). Simi-
lar data were reported in a study conducted in 
Italy where the prevalence of RAL resistance 
mutations was analysed in 156 sequences from 
a subgroup of 120 patients failing RAL: 54 
(36.4%) of the samples had at least one primary 
RAL mutation (Armenia et al. 2015). 
There are currently three published random-
ized studies examining the use of DTG in fail-
ing HIV-1 infected subjects with evidence of 
INSTIs resistance. 
VIKING is an open-label, single-arm trial, de-
signed to evaluate the safety and efficacy of DTG 
in treatment-experienced subjects with geno-
typic evidence of RAL resistance. other antiret-
roviral drug classes (Eron et al. 2013a). Initially 
patients were treated with DTG 50 mg daily. The 
protocol was then amended to include a second 
cohort (DTG 50 mg twice daily) due to low viral 
load response observed in some patients. Pa-
tients in cohort two were also required to have 
one fully active antiretroviral agent in the opti-
mized background regimen. The study consist-
ed of a 10 day functional monotherapy where 
DTG was used in place of RAL in the failing reg-
imen. On day 11, the background regimen was 
optimized based on resistance data. Fifty-one 
patients were enrolled with 27 patients in co-
hort one and 24 patients in cohort two. 
All of the subjects had advanced HIV-1 disease, 
with a median CD4 T cell counts of about 200 
cells/mL. The primary endpoint at day 11 was 
a reduction in plasma viral load of >0.7 log10 
copies/mL from baseline or a viral load <400 
copies/mL. Seventy-eight percent (21/27) of pa-
tients in cohort one and 96% (23/24) in cohort 
two achieved the primary outcome. At week 
24, 11/27 (41%) patients in cohort one and 
18/24 (75%) patients in cohort two achieved a 
viral load <50 copies/mL. The median cell/mL 
increase in CD4 T cells was 54 in cohort one 
and 60 in cohort two. The once- and twice-dai-
ly DTG regimens were both well-tolerated with 
low rates of adverse events, the most frequent 
of which was mild-to-moderate diarrhoea. 
None of the serious adverse events reported 
was judged as related to DTG.
VIKING-3 is a single-arm, open-label phase III 
study, conducted at 65 sites in US, Canada and 
Europe, in which 183 highly treatment-expe-
rienced adults with INSTI-resistant virus re-
ceived DTG 50 mg BID while continuing their 
failing regimen (without RAL or EVG) through 
day 7, after which the regimen was optimized 
with at least 1 fully active drug (Castagna et al. 
2014). Patients had to have plasma viral load 
>500 copies/mL and at least one active antiret-
roviral available for the background regimen. 
Patients on etravirine were only included if it 
was coadministered with LPV/r or DRV/ r. Me-
dian age was 48 years, 77% male, 71% white 
race. Baseline viral load was 4.38 log10 copies/
mL, CD4 140 cells/mL, HCV coinfection rate 
was 14%. Seventy-three percent had baseline 
genotypic and/or phenotypic INSTIs resistance; 
the remaining 27% had historic evidence only. 
At baseline median fold-change to RAL was 
47.5 while the median DTG fold-change was 
1.29. Seventy-three percent of patients had >3 
NRTI major mutations, 70% had >2 major PI 
mutations, and 59% had >2 NNRTI major mu-
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tations. Primary efficacy endpoints were the 
mean change from baseline in plasma HIV-1 
RNA at day 8 and the proportion of subjects 
with HIV-1 RNA <50 copies/mL at week 24. 
Mean change in HIV-1 RNA at day 8 was -1.43 
log10 c/mL, and 69% of subjects achieved <50 
copies/mL at week 24. 
The median change in CD4 T cell count at 
week 24 was 61 cells/mL. Despite the advanced 
population included in this study, DTG 50 mg 
BID had a low (3%) discontinuation rate due 
to adverse events. Virological response was low 
among patients with a DTG fold-change >10 
and those harbouring Q148+ >2 mutations, 
while the group without Q148 mutation had the 
highest response rates. 
Activity of the background regimen did not sig-
nificantly influence day 8 or week 24 response. 
In multivariate analysis, baseline INSTIs re-
sistance and baseline viral load independent-
ly predicted week 24 response. For each two-
fold increase in DTG fold-change, a 63% lower 
chance of achieving viral load <50 copies/mL 
was found. For every 10 fold increase in base-
line viral load, the probability of achieving viral 
load <50 copies/mL was 80% lower. At week 48, 
116/183 (63%) patients maintained a viral load 
<50 copies/mL; among subjects without Q148 
mutation 71% maintained <50 copies/mL
VIKING-4 is a Phase III randomized, double- 
blind study including a placebo-controlled 
7-day monotherapy phase to demonstrate that 
short-term antiviral activity was attributable 
to DTG (Akil et al. 2015). Thirthy adults with 
INSTIs-resistant virus, receiving at screening 
RAL o EVG were randomized to DTG 50 mg 
twice daily or placebo while continuing their 
failing regimen without INI for 7 days. At day 
8, all subjects switched to open-label DTG 50 
mg twice daily and optimized background ther-
apy. The primary end point was change from 
baseline in plasma HIV-1 RNA at day 8. Adjust-
ed mean change in HIV-1 RNA at day 8 was 
-1.06 log10 copies/mL for the DTG arm and 0.10 
log10 copies/mL for the placebo arm (treatment 
difference -1.16 log10 copies/mL [-1.52-0.80]; 
p=0.001). Overall, 47% and 57% of subjects had 
plasma HIV-1 RNA <50 and <400 copies/mL at 
week 24, and 40% and 53% at week 48, respec-
tively. No discontinuations due to drug-related 
adverse events occurred in the study.
Preliminary results documented that optimized 
DTG-containing antiretroviral regimens pro-
vide a substantial initial efficacy rate for salvage 
therapy even in heavily antiretroviral-experi-
enced HIV-2 infected subjects with virus har-
boring resistance to first-generation integrase 
inhibitors (Descamps et al. 2015).
Many in vitro and in vivo data have shown that 
DTG has a higher barrier to resistance com-
pared to the first-generation INSTIs. With the 
expanding use of integrase inhibitors in clinical 
practice, a prompt determination of integrase 
GRT is essential for the optimal management of 
FIGURE 1 - Mutations in the integrase gene associated with resistance to integrase inhibitors (RAL, raltegravir; 
EVG, elvitegravir; DTG, dolutegravir. Adapted from Wensing et al., Top. Antivir. Med. 2014).
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patients failing RAL or EVG. Changes in virae-
mia during virological failure may indicate the 
evolution of RAL resistance and may predict 
the emergence of secondary mutations that are 
associated with a decrease in DTG susceptibil-
ity. 
Early discontinuation of RAL or EVG from fail-
ing regimens may therefore favour subsequent 
salvage with DTG. HIV-1 variants containing a 
combination of resistance mutation at position 
143, 148 and 155 exhibit reduced susceptibility 
to DTG (Figure 1); viruses harbouring muta-
tions belonging to the 148+155 escape pathway 
are less susceptible and exhibit similar or great-
er replicative capacity than viruses harbouring 
mutations belonging to the 143+148 or 143+155 
pathways (Frantzell et al. 2015). 
More data are needed to better understand how 
to guide treatment in subjects harbouring virus-
es with Q-148+ additional integrase mutations. 
More data are needed to explore clinical impli-
cations associated with the substantial further 
decrease in viral replicative capacity observed 
in presence of R263K+M184I/V in comparison 
with the single substitution alone (Singhroy et 
al. 2015). In the meantime, clear-cut results ob-
tained in VIKING studies support a large use 
of DTG 50 mg twice daily in subjects with evi-
dence of INSTIs resistance.
mANAGEmENT OF 
COmORBiDiTiES: FOCUS ON 
KiDNEy AND BONE
Massimo Galli, Andrea Giacomelli, 
Marco Borderi
impact on kidney function
The strongest limitation of current cART is that 
neither HIV eradication, nor a functional cure, 
but only a treatment-dependent blockage of 
HIV replication can be obtained. Consequent-
ly, cART must be taken life-long. This scenar-
io implies to take into account patients’ com-
pliance, the side effects of the different drugs 
and drug combinations used and the possible 
interactions between the antiretroviral drugs 
and other concomitant medication for eventual 
co-morbidities. Therefore the long term posi-
tive effects of cART generally exceed drug relat-
ed side effects and metabolic toxicities (Palella 
1998; Antiretroviral Therapy Cohort Collabora-
tion 2008).
Among the five classes of HIV drugs, the IN-
STIs, since the introduction of RAL in 2008, 
showed a strong antiviral efficacy combined 
with a good safety profile and few drug to drug 
interactions (Messiaen et al. 2013; Liedtke et 
al. 2014). Since the approval of RAL, two new 
different INSTIs has been added to this class. 
EVG, which is a first generation INSTI, is li-
censed in some countries as single-agent tab-
let (Vitekta®), that can be used in combination 
with ritonavir boosted protease inhibitors 
(Deeks 2014) or in other drug combinations 
including a ritonavir boost. Currently, EVG is 
mainly used in a single-tablet combined regi-
men containing fixed doses of TDF/FTC/COBI 
(EVG/COBI/TDF/FTC (Stribild®) (Perry 2014).
COBI, the enhancer used in this fixed combina-
tion, is a potent cytochrome P450 3A inhibitor 
and also inhibits some renal tubular membrane 
transporters such as organic cation transporter 
2 (OCT2), Multidrug and Toxin Extrusion Pro-
tein (MATE)-2-K and most of all MATE-1 (Guti-
errez et al. 2014). The last INSTI approved is 
DTG (Tivicay®) which is the first drug of a sec-
ond generation INSTI, having some new char-
acteristics: a favourable pharmacokinetic pro-
file with a prolonged half-life, reduced drug to 
drug interaction and a different resistance pat-
terns with a significant activity against HIV-1 
strain cross-resistant to RAL or EVG (Messiaen 
et al. 2013; Fantauzzi and Mezzaroma 2014).
Despite a global good safety profile of the IN-
STI class, some concern related to renal toxici-
ties appeared during clinical trials in particular 
regarding the fixed dose formulation of EVG 
including COBI, and DTG (Curtis et al. 2013; 
Elion et al. 2013; Raffi et al. 2013a; Raffi et al. 
2013b). 
The review of the safety data of two phase 
three trials, the GS102 and the GS103 studies, 
showed modest increase in serum creatinine 
and a decrease in estimated creatinine clear-
ance by week 2 of treatment with EVG/COBI/
FTC/TDF, that persists through week 48 and 
over. The mean ± standard deviation changes 
in serum creatinine after 48 weeks of treatment 
were 0.14 mg/dL±0.13 mg/dL in the EVG/COBI/
FTC/TDF arm, 0.01mg/dL ±0.12 mg/dL in the 
EFV/FTC/TDF arm, and 0.09 mg/dL ±0.13 mg/
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dL in the ATV/r plus FTC/TDF arm. Further-
more, 8 (1.1%) subjects in the EVG/COBI/FTC/
TDF arms and 1 (0.1%) subject in the com-
bined comparator arms discontinued the study 
drug due to a renal adverse event. Four (0.6%) 
of the 8 subjects who discontinued EVG/COBI/
FTC/TDF due to a renal adverse event also met 
the FDA criteria for proximal renal tubular dys-
function. The remaining four subjects discon-
tinued study drug due to a renal adverse event 
but did not meet the FDA criteria for proximal 
renal tubular dysfunction. None of the subjects 
in the comparator arms has evidenced of prox-
imal renal tubular dysfunction leading to study 
drug discontinuation. In the four EVG/COBI/
FTC/TDF treated subjects who met the FDA 
criteria of proximal renal tubular dysfunction, 
the laboratory abnormalities improved but did 
not completely resolve upon discontinuation of 
EVG/COBI/FTC/TDF. 
The reason for the increased frequency of prox-
imal tubular dysfunction in the EVG/COBI/
FTC/TDF group versus the comparator arms 
(both of which also included TDF) remains un-
defined (DeJesus et al. 2012; Sax et al. 2012). 
It is well known that EVG/COBI/TDF/FTC pro-
duce an early increment of serum creatinine 
with reduced estimated glomerular filtration 
rate (eGFR) and this arises early during treat-
ment and remains stable over time. This is ex-
plained by COBI inhibition of MATE1, which 
is one of proximal tubular proteins that is in-
volved in creatinine secretion. This can explain 
why a reduction of eGFR can be observed with-
out a decrement of actual GFR (eGFR) during 
treatment with EVG/COBI/TDF/FTC (Manzar-
do 2014; Arya 2013). 
As another drug in this formulation, TDF, is de-
scribed to have nephrotoxic effects, especially 
on proximal tubule, FDA decided that a change 
from baseline of serum creatinine of 0.4 mg/
dL could discriminate between the two differ-
ent nephrotoxic process (De Jesus et al. 2012; 
Sax et al. 2012). From this observation derived 
some recommendations when EVG/COBI/TDF/
FTC is prescribed. 
In particular, eGFR, urine glucose and urine 
proteins should be assessed in all the candi-
dates to this regimen before starting it. More-
over, EVG/COBI/TDF/FTC combination is not 
recommended in patients with an eGFR <70 
mL/min, and the eGFR, urine glucose, urine 
proteins and serum phosphate should be rou-
tinely monitored in all patients for an early de-
tection of proximal tubular dysfunction (Arya 
et al. 2013; Manzardo and Gatell 2014). How-
ever, these renal abnormalities could not be ob-
served when ritonavir is used as pharmacoki-
netic enhancer of EVG instead of COBI.
DTG, the most recent INSTI drug introduced 
in common practice, notably inhibits in vitro 
OCT2 with IC50=1.9µM. This value is 4-fold 
lower than the Cmax of DTG, so a potential inter-
action exists for compounds that undergo renal 
secretion via OCT2 such as serum creatinine 
(Reese et al. 2013). The in vitro studies could 
explain the mild 10-14% decrease in eGFR ob-
served in patients receiving DTG. 
However, this OCT2 inhibition, similarly to 
MATE-1 inhibition induced by COBI, is mild 
and reversible and data from clinical trials 
confirmed that the changes in serum creatinine 
were not related to a real renal blood flow re-
duction or impairment of eGFR. OCT2 is in-
hibited at DTG concentrations below the peak 
reached in clinical trials. 
However, in SPRING-2 study, 48 weeks of DTG 
treatment did not significantly impact renal 
function (Raffi et al. 2013b). Patients receiving 
DTG in this trial had a small mean increase 
in serum creatinine level (grade 1-2) that ap-
pears during the first two weeks of treatment 
and remains stable through week 96 (Raffi et 
al. 2013a). Similarly, the recent results of FLA-
MINGO showed an increment in serum creat-
inine of 0.1-0.2 mg/dL in patients taking DTG. 
The creatinine elevation in patients taking DTG 
is similar in this study to that due to COBI, as 
mentioned before, with a rise in serum creat-
inine level in the first 2-4 weeks of treatment 
(Clotet et al. 2014). 
These data were confirmed at week 96 (Moli-
na et al. 2014b). Interestingly, no differences 
in adverse event related discontinuation have 
been observed in the two arms of the VIKING-3 
study, with a 3% discontinuation in patients 
where DTG was taken at double dose (50 mg 
BID), that was similar to the discontinuation 
rate seen in INSTI-naïve patients receiving 
DTG 50 mg once a day (Eron et al. 2013a; Cast-
agna et al. 2014; Clotet et al. 2014).
In conclusion INSTIs show a good tolerabili-
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ty and safety profile combined with absence of 
significant drug to drug interactions. 
However, some precaution should be adopted 
regarding renal function before prescribing 
EVG in the fixed formulation with COBI.
It is recommended to check eGFR at baseline 
when using EVG/COBI/TDF/FTC and avoid use 
of this compound when eGFR is <70 mL/min. 
A strictly monitoring of kidney function with a 
novel set point of eGFR after one month from 
starting EVG/COBI/TDF/FTC is recommended. 
It is also mandatory monitoring tubular func-
tion by using urine glucose, urine proteins and 
serum phosphate at baseline and then routine-
ly. These procedures are addressed to allow the 
discrimination of an increment of eGFR due to 
impaired creatinine secretion or a more con-
cerning onset of proximal renal tubular dys-
function due to other drug used in the regimen. 
Nevertheless, a serum creatinine change from 
baseline ≥0.4 mg/dL on consecutive visits is 
considered an acceptable threshold for tar-
geting subjects with potentially serious renal 
adverse events who need an enhanced renal 
monitoring. The same procedure is suggested 
for DTG only when it is administered in asso-
ciation with TDF or other potentially nephro-
toxic drugs.
impact on bone
Decreased bone mineral density (BMD) is a 
growing concern for HIV-1 infected patients. 
The incidence of osteopenia/osteoporosis and 
fragility fractures is higher in these patients 
compared to the general population. Although 
HIV-1 patients frequently have more classical 
risk factors for low BMD, both HIV-1 infection 
and cART may also play a potential role, cause 
randomized clinical trials showed a decline in 
BMD by 2-6% over 48-96 weeks. Previous class-
es of ARVs, such as boosted protease inhibitors 
(PI/r) and reverse transcriptase inhibitors, have 
been implicated in altering BMD. Recently, IN-
STI based regimens not containing N(N)RTIs 
(N(N)RTI sparing regimens) or PI/r (PI sparing 
regimens) has gained a wide attention, since 
these combinations can avoid bone N(N)RTI/
PI toxicity. 
Actually, we have BMD data on INSTI-based 
regimens both in naïve (1) and in experienced 
(2) patients.
1. TNF and PI/r use is consistently associated 
with BMD loss in naïve-subjects, so a nu-
cleos(t)ide- or PI/r-sparing regimen would 
ameliorate BMD loss associated with ARV 
therapy initiation. In naïve subjects, there 
are three BMD studies on INSTI plus FTC/
TDF (a), and three BMD studies on INSTI 
plus PI/r (b).
(a)
- GS-US-292-0102 (Sax et al. 2014) is a phase 
2, randomized, double-blind, double-dum-
my, multicenter, active-controlled study. 
Antiretroviral naïve adults with HIV-1 RNA 
≥5,000 copies/mL and CD4 T cell count ≥50 
cells/μL were randomized 2:1 to receive a 
single-tablet regimen of EVG/COBI/FTC/
tenofovir alafenamide (TAF) or EVG/COBI/
FTC/TDF, plus placebo. Over 48 weeks. 
EVG/COBI/FTC/TDF group had changes in 
bone mineral density for hip -2.39% and 
spine -3.37%.
- A5260s (Brown et al. 2014) is a limited site 
Bone Substudy of a large randomized clin-
ical trial comparing TDF/FTC plus ATV/r, 
DRV/r, or RAL (ACTG A5257) to determine 
whether BMD changes over 96 weeks after 
ART initiation differ in HIV-infected per-
sons starting ATV/r, DRV/r, or RAL. 
 At the hip and the spine, the mean percent-
age BMD changes over 96 weeks were not 
different in the PI arms (Hip: ATV/r -3.9% 
vs DRV/r -3.4%, p=0.36; Spine: ATV/r -4.0% 
vs DRV/r -3.6%, p=0.42). At the hip and the 
spine, the loss of BMD was greater in the 
combined PI arms than the RAL arm (Hip 
-3.7% vs -2.4%, p=0.005; Spine: -3.8% vs 
-1.8%, p<0.001).
- GS103 (Clumeck et al. 2014) is a random-
ized, double-blind, active-controlled phase 
3 international trial on EVG/COBI/FTC/TDF 
compared with ATV/r plus FTC/TDF, and 
demonstrated that EVG/COBI was associ-
ated with smaller decreases in BMD over 
144 weeks vs. ATV/r: Hip: -2.83% vs -3.77% 
(p=0.23); Spine: -1.43% vs -3.68% (p=0.018).
(b)
- PROGRESS (Reynes et al. 2013) is a ran-
domized, open-label, 96-week pilot study 
comparing a regimen of lopinavir/ritonavir 
(LPV/r) 400/100 mg twice daily in combina-
tion with either RAL 400 mg twice daily or 
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tenofovir/FTC (TDF/FTC) 300/200 mg once 
daily in ARV-naïve adults. 
 The LPV/r+TDF/FTC group had a statisti-
cally significant (p<0.001) mean percent 
decrease from baseline to week 96 in total 
bone mineral density, which was significant-
ly different from the mean percent change 
in the LPV/r+RAL group (-2.48% vs +0.68%, 
p<0.001).
- In the RADAR study (Bedimo et al. 2014), 
antiretroviral-naıve HIV-infected patients 
were randomized to receive either RAL 
(n=42) or TDF/FTC (n=43), each with DRV/r. 
Changes in subtotal BMD to week 48 were: 
+9.2 with RAL vs.-7 g/cm2 with TDF/FTC 
(p=0.002).
- NEAT (Bernardino et al. 2014) is a phase III, 
randomised, open-label, multicenter, paral-
lel-group, non-inferiority trial in 78 sites in 
15 European countries on HIV-1 ART-näive 
≥18 years subjects with HIV-1 RNA >1,000 
copies/mL, CD4 T cell count ≤500 cells/mL, 
HBs Ag negative, no major IAS-USA RAM, 
randomised 1:1 to DRV+r 800+100 mg QD + 
RAL 400 mg BID or DRV+r 800+100 mg QD + 
TDF/FTC FDC QD over 96 weeks. In lumbar 
spine BMD, mean % change (95% CI) was: 
DRV/r + RAL -0.43 (-1.51, 0.65) vs. DRV/r + 
TDF/FTC -2.8 (-4.0, -1.6); Mean difference 
(95% CI); -2.37 (-4.0, -0.74); p=0.0054. In hip 
BMD, mean % change (95% CI) was: DRV/r 
+ RAL -1.74 (-2.96, -0.52) vs DRV/r + TDF/
FTC -5.99 (-9.18, -2.80); Mean difference 
(95% CI); -4.25 (-7.92, -0.58); p=0.025.
2. Tenofovir and PI/r use is consistently associ-
ated with BMD loss during cART, so a switch 
to INSTI-based regimens would prevent or 
ameliorate BMD loss associated with ARV 
therapy. In experienced patients, there are 
two BMD pre-emptive switch studies on IN-
STI plus PI/r, one BMD pre-emptive switch 
study on INSTI plus FTC/TDF (c), and one 
BMD reactive switch study on INSTI plus 
PI/r (d).
(a)
- KITE (Ofotokun et al. 2012) is a 48 week sin-
gle-center, open-label pilot study in which 60 
HIV-infected adults with plasma HIV-1 RNA 
<50 copies/mL on standard HAART were 
randomized (2:1) to LPV/r 400/100 mg BID 
+ RAL 400 mg BID switch (LPV-r/RAL arm) 
or to continue on standard HAART. No dif-
ference between treatments arms over time 
was significant for total BMD (p=0. 50), pel-
vis BMD (p=0.56), or spine BMD (p=0.72).
- SECOND-LINE (Haskelberg et al. 2014) is a 
96-weeks phase IV multi-centre, open-label, 
randomised controlled trial in HIV-infected 
adults who have virologically failed first-line 
ART consisting of an NNRTI + 2NRTIs ran-
domised to RAL + LPV/r or conventional 2-3 
NRTIs + LPV/r second-line therapy. At week 
96, the mean (standard deviation) percent-
age change from baseline in total hip BMD 
in the NRTI+LPV/r group was -4.1% (5.9%) 
versus -2.2% (4.5%) in the RAL + LPV/r 
group (adjusted treatment difference -1.9%; 
95% confidence interval: -3.4% to -0.4%; 
p=0.012). 
 For lumbar spine, the mean (SD) percent-
age BMD change over 96 weeks in the 
NtRTI+LPV/r group was -4.9% (4.9%) com-
pared to -3.5% (5.0%) in the RAL + LPV/r 
group (adjusted treatment difference -1.9%; 
95% CI -3.3% to -0.5%; p=0.009).
- SPIRAL-LIP (Curran et al. 2012) is a study 
in which patients were randomized (1:1) 
to continue with the PI/r-based regimen or 
switch to RAL, maintaining the rest of the 
treatment unchanged. Total BMD [0.01 (0 to 
0.02) g/cm2, p=0.002], total hip BMD [0.01 
(0 to 0.03) g/cm2, p=0.015] and total hip 
T score [0.12 (-0.05 to 0.21) SD, p=0.004] 
significantly increased with RAL, with no 
significant changes within the PI/r group. 
Differences between treatment groups were 
significant in femoral neck BMD [0.01 (-0.02 
to 0.02) g/cm2, p=0.032] and T score [0.01 
(-0.18 to 0.18) SD, p=0.016].
(b)
- TROP (Bloch et al. 2014) is a multicentre, 
open–label, non-randomized study in 
HIV-infected, osteopenic or osteoporotic 
adults receiving TDF and a PI/r who switch 
from TDF to RAL. Mean % Change from 
Baseline [95% CI] over 48 weeks are: Spine 
3.0 [1.9, 4.0] p<0.0001, Left total hip 2.5 [1.6, 
3.3] p<0.0001, Left femoral neck 2.1 [0.9, 
3.2] p 0.0011, Right total hip 2.7 [1.9, 3.5] 
p<0.0001, Right femoral neck 2.3 [1.2, 3.5] 
p<0.0001.
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3. First results regarding DTG on bone mark-
ers have been recently presented (Tebas et 
al., 2013). In the SINGLE trial, conducted 
in treatment-naive patients to evaluate effi-
cacy and safety of DTG plus Abacavir/Lami-
vudine (ABC/3TC) vs. Tenofovir/Emtricit-
abine/Efavirenz (EFV/TDF/FTC), markers 
of bone turnover (bone-specific alkaline 
phosphatase, C-terminal telopeptide type 1 
collagen, osteocalcin, and procollagen type 
1 N-propeptide) and Vitamin D have been 
measured at baseline (BL) and at 48 weeks. 
DTG + ABC/3TC had superior virologic out-
comes to TDF/FTC/EFV through 48 weeks 
and is associated with smaller changes in 
bone turnover markers. Indeed, after 48 
Weeks, significantly greater changes from 
BL have been observed for all bone mark-
ers (Bone-specific alkaline phosphatase 
p<0.001; C-terminal telopeptide for type 1 
collagen p<0.001; Osteocalcin p<0.001; Pro-
collagen type 1 N-propeptide p<0.001) in 
subjects receiving TDF/FTC/EFV, indicating 
more active bone turnover when compared 
to changes seen in subjects receiving DTG 
+ ABC/3TC. These differences may correlate 
with known TDF-associated changes in 
BMD over time and further study of the po-
tential advantages of a DTG+ABC/3TC regi-
men appear warranted.
In conclusion, INSTI based regimen (plus FTC/
TDF or PI/r) showed improvements in BMD, 
both in naïve and in experienced patients. Al-
though these findings should be confirmed 
with larger studies with longer follow-up, IN-
STI might be considered as a well tolerated 
treatment option in certain patients, especially 
in the HIV-infected aging population, because 
of its potential beneficial bone effects.
AGiNG PATiENTS: CLiNiCAL 
iSSUES AND THERAPEUTiC 
CHALLENGES
Giovanni Guaraldi; Andrea Calcagno
In recent years, the number of elderly persons 
living with HIV-1 has increased (Center for dis-
ease control) as the result of both the availabil-
ity of effective antiretroviral therapy, which has 
reduced AIDS-related mortality, and newly di-
agnosed infections occurring in older adults. It 
is projected that by 2015, more than half of all 
HIV- infected people in the United States will 
be over the age of 50 (US department of health).
The overlapping epidemics between HIV-1 and 
aging, changes profoundly the clinical picture 
of HIV-1 disease. Non-infectious chronic mor-
bidities (NICM) (Shah et al., 2002; Justice 2006; 
Sackoff et al., 2006; Weber et al., 2006; Phillips 
et al., 2008; Vance et al., 2011) that typically 
are highly prevalent in older persons, are often 
superimposed to chronic pathology, murk the 
clinical presentation, interfere with the treat-
ment scheme and contribute to disability and 
mortality. Since cardiovascular disease (CVD), 
hypertension (Htn), bone fractures, renal fail-
ure, diabetes mellitus (DM), neurocognitive 
disorders, cancer and other chronic conditions, 
aggregating in Poly-pathology syndromes, have 
a higher prevalence in HIV-1 infected patients 
in comparison to the general population, it has 
been suggested that HIV-1 in the post-cART era 
has become a syndrome of “accentuated aging 
process” (Guaraldi et al., 2009; Mandalia et al., 
2010), on the contrary it is still a matter of con-
cern if these condition occur at an early age de-
scribing the so call “premature aging process 
(Althoff et al., 2014).
Neither the “accentuated” of the “premature” 
aging conceptualization discriminate what is 
the relative contribution of the host, of the HIV 
virus and of the toxicities of antiretroviral ther-
apy in the development of HIV Associated Non 
AIDS (HANA) conditions, but in the context of 
availability of less toxic and more potent cART, 
the host contribution appear to lead clinical 
risk. 
Host risk can be conceptualized with the defini-
tion of “frailty”: a physiologic state of increased 
vulnerability to stressors, which increases with 
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age but rather represent a true measure of bio-
logical aging, that results from decreased phys-
iologic reserves, and deregulation of multiple 
physiological systems. In the early stages of this 
process, frailty may be clinically silent. Howev-
er, when the losses of reserve reach an aggregate 
threshold that leads to serious vulnerability, the 
syndrome may become detectable by looking 
at clinical, functional and biological markers. 
Understanding and detecting frailty at an ear-
ly stage is important because frailty is not only 
the description of a functional status, but also 
the predictor of future clinical event and overall 
mortality.
Multiple measures exist to identify and mea-
sure frailty. Some are based on clinical judg-
ment or a single item (eg, walking speed), but 
most scales assess multiple domains of age-re-
lated health and grade frailty by counting the 
number of deficits individuals have acquired 
(Theou et al., 2014). 
One commonly used scale, based on the frail-
ty phenotype (Rockwood et al., 2010), identi-
fies frailty by the presence of 3 deficits out of 
5 specific measures: self-reported unintentional 
weight loss >10 lbs or recorded weight loss ≥5% 
in a year, measured slow walking speed, mea-
sured weak grip strength, self-reported exhaus-
tion (3-4 days per week or most of the time), 
and low activity/energy ex- penditure (assessed 
by Minnesota Leisure Time Questionnaire) 
(Womack et al., 2013). 
Another commonly used scale, the “frailty in-
dex,” counts the number of deficits individuals 
have accumulated out of various health mea-
sures and presents them as a proportion (Vigou-
roux et al., 2014). In contrast to the phenotypic 
approach, any measure can be included in a 
frailty index if it is generally related to age and 
poor health, and if the group of items covers 
multiple physiological systems. When at least 
30 items are included, the proportion of deficits 
accumulated appears more informative than 
the specific nature of those deficits. Though the 
effect of each individual deficit may be small, 
their cumulative effects can be large.
So far frailty, which defines age as an health 
condition, has not been mention in any HIV-1 
guideline to make recommendation regarding 
the screening and the treatment of people aging 
with HIV-1.
Nevertheless most guidelines, EACS guideline 
in particular, recommend extensive screening 
for HANA condition, with particular regards to 
patients aged more than 50 years, which may 
in fact help to preserve not only organ function 
but also integrity of the homeostatic mecha-
nisms which regulate interaction between dif-
ferent apparatus and reduce multimorbidity 
onset.
In the absence of any cART studies which have 
analysed frailty as a clinical outcome we need 
to refer to the available data which describe the 
impact of cART regimens on traditional bio-
markers of functional organ reserve. We may in 
fact assume that if we preserve integrity of the 
functional organ reserve we are reducing the 
risk for frailty.
The availability of the new HIV drug class of 
INSTI represent a valuable option for the treat-
ment of HIV infection, not only for the poten-
cy and rapidity in viral replication decay but 
rather for the unique tolerability and potential 
impact in the capacity to contrast mechanisms 
of residual viral burden and secondary reduce 
the burden of chronic inflammation. This is the 
case of the afore mentioned SPIRAL study in 
which the switch out from a boosted PI based 
regimen to RAL was able to significantly reduce 
several inflammatory biomarkers associated 
with cardiovascular diseases including IL6 and 
hrCRP (Martinez et al., 2010).
Participants in SPRING-1 receiving DTG had 
favourable mean changes in plasma lipids from 
baseline compared with those receiving EFV; a 
29-fold greater increase in LDL cholesterol was 
observed in the EFV arm, and mean triglycer-
ide levels fell in the DTG arm (van Lunzen et 
al., 2012).
DTG has also been compared to boosted DRV 
in the FLAMINGO study whose results through 
96 weeks have been recently published (Moli-
na et al., 2015). The study reported interesting 
metabolic data showing a significant reduction 
in the total cholesterol/HDL cholesterol ratio 
which represented the more stringent metabol-
ic parameter in relation to cardiovascular risk. 
Moreover a higher number of grade 2 or higher 
fasting LDL lab abnormalities was shown by 
Week 96 in the DRV/r arm (22%) vs the DTG 
arm (7%), P<0.001 (pre-specified LOCF analy-
sis) (Molina et al., 2014a).
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Particularly interesting are the post hoc 
sub-analyses that have analysed the clinical 
outcome in population stratified by age group 
or by functional organ impairment at baseline.
This is the case of Study 102 and 103, week 144 
Age analyses which depict a non statistical dif-
ference in median change from baseline in TC, 
HDL, LDL and TG in patients aged 50 years old 
or more when compared Stribild© respectively 
to Atripla© or ATV/r + Truvada© (Gazzard et al., 
2014).
The two major studies on Stribild© in experi-
enced patients: strategy PI and strategy NNRTI 
recently presented data with regards to renal 
safety in patients included in the study with 
baseline e-GFR between 79 and 90 ml/min. A 
non significant difference in e-GFR reduction 
was shown in patient starting Stribild© with 
grade 2 GFR impairment. (Reeves et al., 2014).
Our group have recently presents at the 5th 
workshop on HIV&aging a retrospective study 
in which we sought to describe patterns of cART 
use in relation to age and frailty quantified via 
37-item frailty index (FI), based on the cumula-
tive deficits model. FI variables excluded mark-
ers of HIV severity or immune depletion. FI was 
calculated as the proportion of health deficits 
present, and retrospectively assigned for each 
visit. ARV regimens included 2NRTI backbones 
plus either: PI (41%); integrase inhibitor (only 
RAL was available) 22%, or NNRTI (37%). 
Figure 2 shows in each drug class the distri-
bution of patients in relation of age quartiles 
(x-axis) or frailty index quartiles (z-axis) (Guar-
aldi et al., 2014). The distribution of patients 
reflect the choice of clinicians which prefer-
entially select INSTI based regimen in frailest 
patients regardless their age. What we have 
learned so far regarding INSTI in the setting of 
frail patients is promising and this drug classes 
has the potential to represent a “game changer” 
in the treatment of aging patients. We support 
that future randomized clinical trials with INS-
TI may consider frailty index as a clinical end-
point to prove the value of this drug regimen in 
prevention and reversibility of frailty in people 
aging with HIV-1.
FIGURE 2 - Age and frailty spectrum in different ARV drug classes current exposure.
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POLyPATHOLOGy AND 
POLyPHARmACy
Giovanni Di Perri, Stefano Bonora
The use of highly active antiretroviral therapy 
has significantly reduced morbidity and mor-
tality, thus increasing life expectancy of HIV-1 
infected individuals, transforming HIV-1 infec-
tion into a chronic disease.
A major focus of antiretroviral research has 
been simplification of cART therapy. Many 
low-pill burden, once daily regimens are now 
available, improving adherence and making 
treatment-success achievable for many more 
patients. However, as HIV-1 patients live-lon-
ger, they may develop chronic diseases of aging, 
many of which occur with increased frequency 
compared to the general population. Treatment 
of these illnesses complicates care by increas-
ing pill burden, creating drug-drug interactions 
and may jeopardize the gains achieved by cART 
simplification. For many patients overall pill 
burden has not significantly changed due to 
the non-HIV-1 medication pill burden (Krentz 
et al. 2012). As a consequence of both HIV and 
comorbid disease burden, polypharmacy and 
medication-related problems are emerging as 
an important challenge facing older HIV-infect-
ed adults.
Polypharmacy was defined as intake of 5 or 
more non antiretroviral compounds. Interplay 
between polypharmacy and anti-HIV-1 drugs 
has not been yet fully investigated as potential 
impact on adherence, safety and potential for 
drug-drug interactions.
Data gaps could be identify in 3 main fields.
The first is the impact on global tolerability of 
therapy: the question is whether and to what 
extent polypharmacy and antiretroviral drugs 
could have additional or overlapping effect in 
terms of toxicity and tolerability. One of the 
few data available is the report of Veterans Co-
hort on polypharmacy in HIV-1 infected and 
uninfected people (Edelman et al. 2013). An 
analysis of mortality adjusted for gender, race/
ethnicity and VACS index score showed an in-
creasing hazard of death in those prescribed 3 
or more medications, reaching about 2-fold for 
HIV-1 infected patients prescribed 5 or more 
medications. The association of polypharma-
cy with increased mortality is concerning but 
the cause is unclear. Most likely, greater mor-
tality is simply due to more severe underlying 
comorbid illnesses. However, it is possible that 
patients receiving polypharmacy have more 
toxicity and/or lower treatment efficacy result-
ing from drug-drug interactions or reduced ad-
herence. Availability of antiretrovirals with very 
few long-term tolerability issues, as integrase 
inhibitors, could decrease such risk over time. 
However more clinical data should be obtained 
from cohort studies.
The second main data gap is impact on adher-
ence. While adherence of antiretrovirals has 
been fully investigated in last decades, scarse 
data are available on reciprocal effect between 
HIV and non-HIV drugs on adherence (Elzi et 
al. 2010; Juday et al. 2011). Impact of comor-
bidities on HIV-1 medication persistence was 
retrospectively evaluated in a US database 
(Maiese et al. 2012). This analysis of healthcare 
and pharmacy claims data including 3,057 pa-
tients found a relationship between increasing 
number of comorbidities and discontinuation 
of cART. Patients with 1, 2, and 3 or more co-
morbidities had a 6% (p=0.528), 28% (p=0.014), 
and 31% (p=0.02), respectively, higher risk of 
cART discontinuation compared with patients 
with no comorbidities. While multiple factors 
may be at play, polypharmacy may contribute 
to these findings. No study, however, have so far 
investigated the effect of schedule and number 
of non-HIV-1 drugs on adherence of anti-HIV-1 
medications, and viceversa. Such impact could 
theoretically different in newly discovered HIV-
1 positive patients starting HIV-1 drugs while 
already taking since long time a number of non-
HIV medications, as compared to subjects in 
follow up who add an increase number of con-
comitant compounds to a stable HIV-1 regimen.
The third point is potential for drug-drug in-
teraction. Many studies, after the first report 
by the Swiss Cohort (Marzolini et al. 2011), fo-
cused on an high risk of drug-drug interactions 
in HIV-1 positive patients administered with 
concomitant medications. Most of the drugs, 
in fact, share the same metabolic pathways of 
antiretrovirals, namely CYP3A4/5-based metab-
olism. For instance, a study reviewed the prev-
alence and risk factors for clinically significant 
drug interactions with cART, and it was found 
that those subjects aged >42 years with more 
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than three comorbidities and a treatment plan 
consisting of a PI were at an independently in-
creased risk of a clinically significant drug in-
teraction (Miller et al. 2007). Therefore, use of 
antiretrovirals with a metabolism not primar-
ily involving cytochrome P450 is warranted in 
these patients. In any case, no interaction data 
of a number of drugs are available (e.g anti-
convulsants or antiarrhythmic), and clinical 
significance of a known interaction is not easy 
to evaluate in the single patient. Most cohort 
studies including clinical follow up of patients 
with polypharmacy and high risk of drug-drug 
interaction are requested. Moreover, clinicians 
must to be aware of the impact of unpredictable 
drug-drug interaction in the clinical setting. A 
very recent example from anti-HCV treatment 
(FDA), where FDA is warning that serious slow-
ing of the heart rate can occur when the anti-
arrhythmic drug amiodarone is taken together 
with sofosbuvir taken in combination with an-
other direct acting antiviral for the treatment of 
HCV infection.
In conclusion, patients with HIV-1 infection 
have several comorbidities requiring multiple 
pharmacotherapies that can increase their risk 
of polypharmacy and related adverse events. 
However, little is known about the impact of ag-
ing on medication use in HIV-1 infected older 
individuals, the potential for interactions with 
cART and administered medications, and the 
impact of this on therapy tolerability and vi-
rological response with aging. Reducing pill 
burden, careful titration of medications, and 
increasing awareness of common DDIs can 
prevent coadministration of potentially harm-
ful combinations and reduce unnecessary poly-
pharmacy-related adverse events in this popu-
lation.
OPPORTUNiTiES FOR iNTEGRASE 
iNHiBiTOR THERAPy iN SPECiAL 
PATiENT POPULATiONS
Cristina Mussini, Antonio Di Biagio
Given the potency and the relative safety of the 
INSTIs in initial trials and in clinical practice, 
there has been considerable interest in explor-
ing their role in different group of HIV-1 infect-
ed patients.
integrase inhibitors in HiV-infected patients 
with high viral load
Data from randomized trials and observational 
studies have shown that patients with high viral 
load are among those most difficult to treat. In-
deed, the higher baseline HIV-1 RNA is a mark-
er of treatment failure (Santoro et al., 2013). 
The drug-class of integrase inhibitors, charac-
terized by a rapid viral decay resulted in a good 
option for these patients since has reached good 
virological results either compared to EFV or 
to protease inhibitors. In the SINGLE study 
the overall difference in treatment response in 
favour of DTG was also observed among pa-
tients with HIV RNA >100,000 copies/mL as 
well as those with HIV RNA ≤100,000 copies/
mL (Walmsley et al., 2013). The SINGLE study 
results are consistent with rates in STARTMRK 
(Lennox et al., 2009). Both regimen showed vi-
rologic success also in patients with baseline 
HIV-RNA >100,000 copies/mL. In the SAILING 
Study, DTG performed better than RAL in pa-
tients experienced with HIV-RNA >50,000 cop-
ies/mL (Cahn et al., 2013). Moreover, in the Fla-
mingo Study patients in DTG-based regimens 
had a better response rate among people start-
ing treatment with a viral load above 100,000 
copies (Clotet et al., 2014). Also the new single 
tablet regimen containing EVG/COBI/FTC/TDF 
showed better response rate than EFV/FTC/
TDF and FTC/TDF and ATV/r in patients with 
baseline HIV-1 RNA >100,000 copies/mL (DeJe-
sus et al., 2012; Zolopa et al., 2013).
These data are confirmed in clinical practice, 
indeed, a recent Italian cohort study showed 
that an INSTIs based regimen allows obtaining 
a higher probability of success in a group of pa-
tients with high viral loads at baseline (INSTI 
vs.boosted PI HR 3.23; P<0.001) (Di Biagio et 
al., 2014). In the ACTG 5257, a comparative, 
randomized, clinical trial, first-line RAL proved 
superior to PI/r (ATV/r and DRV/r) in an end-
point combining virologic efficacy and safety. 
The analysis involved 1809 eligible patients, 
30% of participants had a pretreatment HIV-
RNA >100,000 copies/mL (Lennox et al., 2014).
integrase inhibitors in advance naïve 
patients
Among patients who may benefit from an INS-
TI-containing regimen we could include those 
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with a low CD4 T cell count at diagnosis. In-
deed, some trials have shown an increase in 
CD4 T cell count in subjects receiving this drug 
class, which could be clinically relevant in this 
group of patients. In the SINGLE Study the au-
thors observed a statistically superior response 
in favours of DTG plus ABC/3TC in change 
from baseline in CD4 T cell counts at week 48 
(267 cell/mL vs 208 cells/mL; p<0.001).
In the STARTMRK study the mean CD4 T cell 
count at randomization was 219 (SD 124) 
cells/mL and the mean changes from baseline 
CD4 T cell count were 332 and 295 cell/mL 
in the RAL and efavirenz arms, respectively 
(Lennox et al. 2010). In the SAILING Study 
the CD4+ cell count at baseline in the DTG 
arm was 204.5 cells/mL (88-368), while in the 
RAL arm was 193.0 cells/mL (96-365). CD4 T 
cell counts increased from baseline to week 
48 in both groups (mean change 162 [SD 151] 
cells/mL in the DTG group; 153 [144] cells/mL 
on RAL). In the FLAMINGO the median CD4 
T cell count gain measured 210 in both treat-
ment groups.
In the ACTG 5257, at baseline 30% of partici-
pants in either group had CD4 T cell count <200 
cells/mL, and the mean change in CD4 T cell 
count from baseline was: 256 (240-271) cells/
mL in DRV/r arm; 284 (269-300) cells/mL in AT-
V/r arm and 288 (272-304) cells/mL in RAL arm 
(Lennox et al. 2014).
integrase inhibitors in women 
of childbearing age
RAL and DTG do not have any drug-drug in-
teractions with oral contraceptive, while, since 
EVG/COBI are metabolized by CYP3A and 
COBI is also to a minor extent by CYP2D6, 
there could be significant interactions with 
hormonal contraceptives. RAL and DTG may 
be given with estrogen/progestin oral contra-
ceptives (Anderson et al. 2011).
integrase inhibitor use in pregnancy
Integrase inhibitors, as all other antiretrovirals, 
are not licensed for the use in pregnancy and 
to date data are limited. RAL is classified as an 
FDA pregnancy category C, DTG and EVG are 
classified as category B (DHHS Panel on Treat-
ment of HIV-Infected Pregnant Women and 
Prevention of Perinatal Transmission 2014). 
Nevertheless, despite the absence of any antiret-
roviral drug in class A, a suppressive antiret-
roviral regimen is mandatory not only for the 
health of the mother, but even more important-
ly to avoid transmission of HIV-1 infection to 
the baby. Indeed, the use of integrase inhibitors 
is particularly important in those who arrive at 
HIV-1 diagnosis very close to the delivery, since 
it is fundamental the rapid decay of viremia in 
the attempt to avoid peri-partum HIV-1 trans-
mission (Westling et al. 2012; Cha et al. 2013; 
De Hoffer et al. 2013; Taylor et al. 2013; DHHS 
Panel on Treatment of HIV-Infected Pregnant 
Women and Prevention of Perinatal Transmis-
sion 2014).
Paediatric and adolescents patients
The impressive antiviral potency, the conve-
nience of dosage and the excellent tolerability 
profile make integrase inhibitor an attractive 
option for children and adolescent younger 
than 16 years of age, even if, at present, data are 
limited. RAL is FDA-approved for use in infants 
and children aged ≥4 weeks and weight ≥3 kg. 
Current paediatric approval and dosing recom-
mendations are based upon evaluations in 122 
patients aged ≥4 weeks to 18 years enrolled in 
IMPAACT P1066.
DTG is FDA-approved in combination with 
other antiretroviral drugs for children aged 12 
years and older, weighing at least 40 kg, and 
who are treatment-naïve or treatment-experi-
enced and INSTI-naïve. 
A clinical trial, IMPAACT P1093, is an ongoing 
open-label trial of HIV-infected children with 
the plan to enrol down to age 4 weeks. FDA ap-
proval of DTG down to age 12 years was based 
on data from 23 treatment-experienced, INS-
TI-naïve adolescents. Neither EVG nor TDF/
FTC/EVG/COBI is FDA-approved for use in 
children aged <18 years (DHHS Panel on An-
tiretroviral Therapy and Medical Management 
of HIV-Infected Children 2014).
Gaps Still present:
1. To evaluate their efficacy in late presenter 
patients.
2. To evaluate in cohort study if there is any pe-
culiar advantage of this drug class concern-
ing hard clinical end-points.
3. To evaluate if the rapid viral decay could 
have an impact on chronic inflammation.
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HiV/HCV-COiNFECTED PATiENTS
Massimo Puoti; Raffaele Bruno; 
Valentina Zuccaro
Antiretroviral treatment for HIV-1-infected 
treatment naïve and -experienced patients has 
substantially improved over the past 10 years 
with the approval of several new drugs from 
existing classes, such as protease inhibitors 
(e.g., DRV), and novel classes, such as chemo-
kine inhibitors (CCR5) (e.g., maraviroc), and, 
in particular, integrase inhibitors (RAL, DTG 
and EVG/COBI/FTC/TDF single-tablet regimen 
[Stribild©]). As a result, life expectancy has im-
proved, approaching that of uninfected individ-
uals, based on a recent analysis of 4,600 asymp-
tomatic treatment-naïve HIV-infected patients 
in high-income countries (Mocroft et al. 2003). 
The increased longevity, however, also necessi-
tates consideration of the increasing incidence 
of HANA conditions, commonly associated 
with advancing age and chronic inflammation, 
including liver disease, among other comorbid-
ities (Puoti et al. 2012). 
A multi-target clinical strategy has been pro-
posed to decrease liver-related morbidity and 
mortality in people living with HIV-1; this strat-
egy should include: hepatitis B vaccination and 
optimization of dual anti-HIV-1and anti-HBV 
therapy, screening for and proactive treatment 
of alcohol abuse, optimization of cART, man-
agement of insulin resistance, prompt diagno-
sis and treatment of glucose intolerance and 
diabetes (Puoti et al. 2013a). However, since 
HCV coinfection is the most important cause 
of liver disease in HIV-1 infected population, a 
“screen and treat” strategy for HCV coinfection 
is, at least in theory, the most effective and rele-
vant measure to decrease liver-related mortality 
among HIV-1 infected patients. In fact, overall 
mortality in HIV/HCV co-infected patients from 
the VA cohort has not significantly decreased 
from 1996 (pre-cART era) to 2009, because 
HIV-1 related mortality has been replaced by 
HCV-related mortality (Puoti et al. 2013b). 
In addition to its impact on liver-related mor-
bidity and mortality, HCV co-infection in HIV-
1 infected individuals has been independent-
ly associated with an increased incidence of 
renal failure and pathological hip. There are 
also controversial data about an unfavourable 
impact of HCV co-infection on progression of 
HIV-1 infection towards AIDS and on CD4 T 
cell recovery after cART. 
These discordant results could be due to con-
founders associated with HCV coinfection (his-
tory of injection drugs use, low socioeconomic 
status, African American ethnicity), thus the 
worsening role of HCV co-infection on HIV dis-
ease evolution, and response to anti-HIV treat-
ment is still debated (Puoti et al. 2013b).
Characteristics of the “ideal anti HiV 
therapy in HCV co-infected patients”
For these reasons the ideal antiretroviral drug 
for HIV HCV co-infected patients should be:
- Effective on HIV disease to counteract wors-
ening impact of HCV coinfection.
- Kidney and bone friendly with anti HIV ac-
tivity in CNS.
- Not associated with insulin resistance, lipo-
dystrophy and dyslipidemia.
- Without significant metabolic impact and 
hepatotoxicity in HIV+.
- Without drug drug interactions with anti 
HCV drugs.
- Safe in patients with End Stage Liver Dis-
ease.
The efficacy on HIV-1 disease and the impact 
on metabolic, renal and bone related comorbid-
ities of integrase inhibitors have been illustrat-
ed in other reviews.
This chapter will be focused on hepatotoxici-
ty, drug-drug interactions with anti HCV drugs 
and pK and safety in patients with end stage 
liver diseases of integrase inhibitors.
Hepatic Safety of integrase inhibitors
in HCV co-infected patients
Of the integrase inhibitors in clinical develop-
ment, currently available data concerning the 
use of INSTIs in HCV co-infected patients de-
rive from clinical trials. In treatment naive pa-
tients, protocol 021 of the STARTMRK study, 
7% of patients enrolled in this trial were either 
hepatitis B or C co-infected. Grade 3 or 4 lab-
oratory abnormalities occurred at similar fre-
quencies within the EFV based arm and the 
RAL based arm with regard to ALT, AST, or al-
kaline phosphatase or total bilirubin elevations 
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fected patients is available at present from the 
phase III studies. Patients with chronic active 
hepatitis B and/or hepatitis C co-infection were 
permitted to enroll provided that the liver func-
tion tests, i.e. AST, ALT and alkaline phospha-
tase, did not exceed five times the upper limit 
of normal. Overall 113 of 699 patients were ei-
ther co-infected with hepatitis B or hepatitis C 
or both (16.2%). In general, the safety profile of 
RAL in patients with hepatitis B and/or hepati-
tis C co-infection was similar to that in patients 
without hepatitis B and/or hepatitis C co-in-
fection. Liver related laboratory abnormalities 
occurred at similar frequency within RAL and 
optimized background treatment arms. As ex-
pected, in hepatitis co-infected patients eleva-
tions of AST, ALT or total bilirubin were more 
often found, in 31%, 31%, and 16% of patients, 
respectively, as compared to 9%, 8%, and 8% 
of all other RAL-treated subjects. Two recent 
investigator initiated studies from Spain and 
the UK have also reviewed the hepatic safety of 
RAL in HCV co-infected patients. A single cen-
ter study from Spain evaluated 218 HIV-posi-
tive patients who had received RAL as part of 
HAART. Apart from being part of a rescue reg-
imen, RAL was prescribed in 59% of patients 
because of poor tolerance or side effects with 
an otherwise virologically suppressive regimen. 
Ninety-two (42%) were HCV positive. In this 
study any grade of ALT elevation was observed 
in 8% of HIV and 25% of HCV/HIV co-infected 
patients (p<0.001). Only three ALT elevations 
grade 3 or 4 were observed among HCV-posi-
tive patients, however all were considered not 
related to RAL. Among HCV-negative patients 
no grade 3 or 4 ALT elevation was observed. In 
a UK study 13 patients co-infected with HIV 
and HCV were switched from a PI (n=7), NN-
RTI (n=4), or NRTI only (n=2) to a RAL based 
cART. The mean ALT at baseline and three 
months was 247 U/l and 176 U/l, respectively. 
Eight patients experienced sustained improve-
ments in the ALT at three months, though the 
reduction in mean ALT from baseline to three 
months after commencing RAL was not statis-
tically significant (p=0.1). Across DTG clinical 
program, the percentage of participants with 
hepatitis B or C co-infection ranged from 7% 
to 11% in the three studies conducted in treat-
ment-naive patients wherease it was 13 % in 
treatment-experienced trial (Min et al., 2014). 
The incidence of aspartate aminotransferase 
and alanine aminotransferase elevations in in-
dividuals with HBV/HCV infection and treated 
with DTG was lower than in RAL- and EFV/
TDF/FTC-treated ART-naive individuals but 
higher than in the DRV/r-treated group. The in-
cidence of liver chemistry toxicities for subjects 
without hepatitis virus infection was similar in 
the DTG, RAL, and EFV groups, but lower in 
the DRV+ RTV group.
ART-experienced individuals coinfected with 
HBV and/or HCV who received DTG were not-
ed to have more frequent liver enzyme eleva-
tions. Grade 3 to 4 elevations in total bilirubin 
were invariably associated with atazanavir ad-
ministration in both DTG and RAL treatment 
arms (Curtis et al., 2014). 
In a small group of HCV co-infected subjects, 
switch from PI/r or NNRTI in combination with 
FTC/TDF to Stribild© was safe. At baseline, 
some subjects previously on EFV or ritonavir 
boosted PI had elevated ALT and/or AST levels. 
No grade 3 or 4 ALT and/or AST elevations or 
evidence of drug induced liver injury in the STB 
group up to week 48.
In summary integrase inhibitors appears to 
have a favorable hepatic safety profile and in-
creased rates of ALT elevations among hepa-
titis co-infected patients are similar to those 
observed with other recent new drugs in other 
clinical trials and cohorts (Vogel and Nelson 
2009).
integrase inhibitors and anti HCV Therapy
Indications for HCV treatment in HCV/HIV 
co-infected persons are identical to those in pa-
tients with HCV mono-infection. Regardless of 
the respective costs of these options, IFN-free 
regimens are the most attractive options when 
available in HCV mono-infected and in HIV/
HCV co-infected patients. The same IFN-free 
treatment regimens can be used in HIV-co-in-
fected patients as in patients without HIV-1 
infection, as the virological results of therapy 
are identical. The use of COBI-based regimens, 
EFV, delavirdine, ETR, nevirapine, RTV, and 
any HIV protease inhibitor, boosted or not by 
ritonavir, is not recommended in HIV-1 in-
fected patients receiving simeprevir. The daily 
daclatasvir dose should be adjusted to 30 mg 
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daily in HIV-1 infected patients receiving AT-
V/r and to 90 mg daily in those receiving EFV. 
No drug-drug interaction has been reported 
between sofosbuvir and antiretroviral drugs. 
The fixed-dose combination of sofosbuvir and 
ledipasvir can be used with all antiretrovirals. 
However, this regimen should not be used with 
the combination of tenofovir/FTC with ATV/r, 
DRV/r, LPV/r or EVG/COBI when possible, or 
used with caution with frequent renal moni-
toring. The combination of ritonavir-boosted 
paritaprevir, ombitasvir and dasabuvir should 
not be used with EFV, ETR or nevirapine and 
rilpivirine should be used cautiously with re-
peat ECG monitoring. ATV and DRV should be 
taken without ritonavir and other protease in-
hibitors are contraindicated. EVG/COBI should 
not be used with this regimen because of the 
additional boosting effect. As far as concomi-
tant use of HIV drugs and FDA-approved HCV 
drugs for treatment of HCV in HIV-Infected 
Adults, INSTIs seem to show less significant 
drug-drug interactions with any HCV drugs 
compared to other ARV classes although, with-
in INSTIs, RAL and DTG offer a better profile 
than EVG, that is co formulated with cobicistat 
(DHHS Panel on Antiretroviral Guidelines for 
Adults and Adolescents 2014).
integrase inhibitors and End Stage 
Liver disease
Several ARVs have been evaluated in the setting 
of liver impairment to evaluate potential chang-
es in PK and safety. 
For ritonavir boosted PIs, for a given degree of 
impairment, the exposure changes vary consid-
erably depending on the PI. Boosted-DRV ex-
posures are unchanged with mild impairment, 
while the AUCtau and concentrations at 12 h 
after dosing (C12 h) of boosted tipranavir are 
30% and 84% higher, respectively. 
In patients with moderate hepatic impairment, 
DRV AUCtau values were 20% higher than those 
in matched controls, despite 2-fold higher RTV 
Cmin levels, indicating the independent effects 
of liver impairment on the PK of these agents.
No clinically relevant changes in RAL, DTG or 
EVG or COBI PK were observed following mul-
tiple-dose administration in subjects with mod-
erate liver impairment versus matched control 
subjects and the study treatments were well 
tolerated; these findings can be extrapolated to 
mild hepatic impairment.
Accordingly, RAL, DTG and EVG, as an individ-
ual agent or as a component of EVG/COBI/FTC/
TDF, may be administered without dose adjust-
ment to HIV-1 infected patients with moderate 
or mild hepatic impairment. 
There are no data on boosted EVG in subjects 
with severe impairment. RAL plasma levels 
are increased in HIV/HCV co-infected patients 
with advanced liver cirrhosis (Child-Pugh C). 
Despite the higher exposure, RAL was safe and 
well tolerated (Hernandez-Novoa et al. 2014).
Conclusions
New antiretroviral agents like the integrase in-
hibitors offer the opportunity to maintain or 
promote CD4 T cell increase and a prompt and 
durable HIV-1 suppression, to treat HIV-1 with 
a minimal impact on renal function, metabolic 
disturbances and bone metabolism with mini-
mal hepatotoxicity and a potential for adminis-
tration in End Stage Liver Disease. 
In addition they offer the opportunity of modify 
cART for the duration of anti-HCV therapy to 
circumvent interactions with ribavirin, or the 
new anti HCV drugs and especially with regi-
men including anti HCV protease inhibitors or 
ledipasvir. 
Thus RAL, EVG and DTG, may constitute a rel-
evant treatment options in the setting of HIV-1 
and HCV co-infection.
TREATmENT iNTENSiFiCATiON 
WiTH iNTEGRASE iNHiBiTORS  
AND THE CNS RESERVOiR
Andrea Antinori, Paola Cinque
HIV-1 integrates into the host genome, and CD4 
T cells can harbour latent, replication compe-
tent HIV-1 DNA for several years. This latent 
reservoir may be resistant to therapy, result-
ing in lifelong infection. Despite the sustained 
suppression achieved by cART in plasma, HIV-
1 persists in long-lived cellular reservoirs, and 
low-level ongoing viral replication, undetect-
able by standard test, may be detected in plasma 
by ultrasensitive assays. Whether this low-level 
viremia is related to viral replication or release 
of virus from stable reservoirs without evidence 
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of replication remains controversial. Howev-
er, even without ongoing cycles of replication, 
HIV-1 virions are persistently produced and re-
leased. The association between reservoir size 
and immune activation during cART (Hatano 
et al. 2013a) suggests that cellular reservoirs 
may contribute to chronic inflammation and 
potentially to HIV morbidities in HIV individ-
uals with durable cART-induced suppression 
of HIV-1 replication (Deeks et al. 2013). The 
central nervous system (CNS) is considered an 
anatomic reservoir where HIV-1 can persist de-
spite suppressive therapy and replicate at low 
level, due to low penetration of several antiret-
roviral drugs across the blood-brain barrier 
(Dahl et al. 2014). The development of the IN-
STIs antiretroviral drug class opens new inter-
esting perspectives in treatment control of HIV-
1 reservoirs, relating to both their mechanism 
of action and the possibility of penetration and 
acting in “sanctuary sites”.
In this perspective, we will review pharmaco-
kinetics studies addressing INSTIs penetration 
in the CNS, their in vitro properties to inhibit 
HIV-1 in cells from the monocyte-macrophage 
lineage, and the effect of cART intensification 
using INSTIs on cerebrospinal fluid (CSF) 
markers of replication and immune activation.
Cerebrospinal fluid pharmacokinetics 
studies
Most of the CSF pharmacokinetics studies have 
involved RAL and investigated its CSF concen-
trations in relation to in vitro inhibitory con-
centrations, plasma levels, permeability status 
of the blood-brain barrier and presence of poly-
morphisms in RAL transporter genes. 
Overall, RAL penetration in CSF varies largely 
among subjects, with a variable proportion of 
patients achieving drug concentrations above 
the reported inhibitory concentrations for wild-
type HIV-1 (Yilmaz et al. 2009; Croteau et al. 
2010; Calcagno et al. 2014). Indeed, the propor-
tion of patients with RAL CSF levels above the 
inhibitory concentrations (IC) depended on the 
reference value used, e.g., IC50% vs IC90% or 
IC95%. For instance, CSF RAL concentrations 
exceeded the IC95% levels for wild-type HIV-1 
strains in approximately 50% of 25 specimens 
and in 29% of 41 specimens in two different 
studies (Yilmaz et al. 2009; Croteau et al. 2010; 
Calcagno et al. 2014). On the contrary, CSF 
drug concentrations exceeded the IC50% for 
wild-type HIV-1 in all of 21 patients, by a me-
dian of 4.5 fold and in all of 41 patients in two 
different series (Croteau et al. 2010; Calcagno 
et al. 2014). 
Thus, if IC95% values are used as reference, 
only a proportion of patients seem to achieve 
inhibitory CSF RAL concentrations. 
CSF RAL concentrations were higher in pa-
tients with higher albumin CSF: plasma quo-
tient and CSF albumin concentrations, reflect-
ing higher barrier permeability, and in those 
with higher plasma RAL concentrations (Yil-
maz et al. 2009; Croteau et al. 2010; Calcagno 
et al. 2014). In an attempt to better define CSF 
pharmacodynamic targets, inhibitory quotients 
(IQ, CSF concentrations divided by in vitro 50% 
and 95% inhibitory concentrations) were calcu-
lated for different drugs and an adequate expo-
sure was considered if IQ95 was >1. Compared 
to other drugs, and despite high CSF: plasma 
ratios, of an average of 17%, RAL recipients 
showed a low IQ95, of 0.7, resulting from the 
high proportion of samples with concentra-
tions below the IC95% (Calcagno et al. 2015). 
However, because of large inter-patient and 
intra-patient concentration variability, general-
ized definitions for adequate CSF exposure may 
not always apply to individual cases.
The CSF RAL concentrations were also com-
pared between patients with or without certain 
polymorphisms of cell membrane efflux trans-
porter genes, to investigate whether altered 
expression of transporters - used by RAL to 
cross the blood-brain barrier - could be asso-
ciated with differences in CSF drug concentra-
tion. Several membrane transporters expressed 
in the blood-brain barrier were investigated, 
including the major transport protein P-gly-
coprotein (Pgp), coded by the ATP-binding 
cassette sub-family B member 1 (ABCB1) and 
the ATP-binding cassette sub-family G mem-
ber 2 (ABCG2), expressed by the homonymous 
gene. No different CSF RAL concentrations 
were found between patients with different 
ABCB1 variants, including the 3435C→T vari-
ant, which is associated with different Pgp ex-
pression level (Johnson et al. 201s3; Calcagno 
et al. 2014; Tsuchiya et al. 2014). In contrast, 
RAL concentrations in CSF, but not plasma, 
M. Andreoni, et al.474
were lower in CA and AA genotype holders at 
position 421 in the ABCG2 gene compared to 
CC genotype (Tsuchiya et al. 2014). Because 
these C to A nucleotide substitutions reduce 
transporter expression, they may impair RAL 
transport from blood to CSF, resulting in low 
CSF concentrations. 
The fact that ABCG2 is diffusely expressed, 
whereas ABCB1 is only weakly expressed on 
the CSF side of choroid plexus epithelial cells, 
suggests that ABCG2 expression level is more 
likely to influence CSF RAL concentration than 
ABCB1. Finally, an association was also found 
between lower CSF RAL concentrations and 
the 613 CG genotype in the gene encoding the 
hepatocyte nuclear factor 4 a (HNF4a), an in-
tranuclear factor that contributes to expression 
of OAT1, another RAL brain barrier transport-
er (Calcagno et al. 2014). Overall, it seems that 
polymorphisms in the transporter genes might 
influence the CSF RAL penetration. However, 
given the current evidence, they seem more to 
contribute to the large concentration variabil-
ity observed among patients than to represent 
a potentially useful marker of CSF RAL pene-
tration.
Beyond RAL, there is no published data on the 
CSF pharmokinetics of EVG, and only initial, 
although encouraging data on DTG. A recent 
study of a group of 11 naïve patients showed 
CSF DTG concentrations similar to unbound 
plasma concentrations and exceeding the in 
vitro IC50% for wild-type HIV-1 in all of the 
cases (Letendre et al. 2014). Of note, DTG CSF 
concentrations exceeded the IC50% value by 
90-fold at week 2 and by 66-fold at week 16, 
i.e., figures that were much higher than those 
observed with RAL (Croteau et al. 2010). The 
clinical relevance of these findings is unknown, 
however, the high CSF DTG concentrations, to-
gether with its known activity against most in-
tegrase inhibitor single-mutant viruses suggest 
an effect of DTG also in case of resistance to 
integrase inhibitors, including in the CNS.
In vitro studies of integrase inhibitors 
susceptibility on macrophage cells
Recent in vitro studies showed that the an-
ti-HIV-1 activity of RAL in macrophages was 
similar or slightly higher than that observed in 
PBMCs and T cell lines (Scopelliti et al. 2011). 
Despite significantly lower intracellular con-
centrations in macrophages than in lympho-
cytes, however, RAL was similarly effective in 
inhibiting HIV-1 replication, both in resting 
and activated macrophages (Gavegnano et al. 
2013). The efficacy of RAL on macrophage cell 
infection was also confirmed by measurement 
of pro-inflammatory cytokines in tissue culture 
supernatants from primary brain derived mac-
rophages infected with HIV-1 and treated with 
RAL. 
Indeed, RAL significantly suppressed or de-
creased the rate of cytokine production in HIV-
1 infected microglia, including IFN-γ, IL-10, IL-
12-p70, IL-1, TNFa and IL-6 (Tatro et al. 2014). 
In general, these in vitro studies support the 
efficacy of RAL also in CNS macrophages and 
their potential in inhibiting CNS HIV-1 replica-
tion.
During macrophage infection, however, the 
presence of a single primary RAL resistance 
mutation (Q148H, Q148R, N155H, or N155S) 
was sufficient to confer virus resistance, simi-
larly to what is observed in co-stimulated CD4 
T cells (Canducci et al. 2011). On the other 
hand, single mutations were associated with a 
different level of susceptibility to RAL and EVG 
in human primary monocyte derived macro-
phages, and DTG was able to inhibit infection 
of RAL-resistant N155H and Y143C mutants 
in these cells (Marsden et al. 2011; Pollicita et 
al. 2014). These observations suggest that mac-
rophages, which may play a role as a reservoir 
of HIV infection, may also enable the develop-
ment of RAL resistance. In this view, the effica-
cy of DTG in macrophages, including against 
RAL-resistant mutants, may be clinically rele-
vant.
iNSTi intensification and effects 
on reservoirs
Several studies have been implemented using 
an INSTI for the intensification of cART regi-
mens in HIV-1 infected individuals with stable 
virological suppression. An increase of episo-
mal circular DNA forms (2-LTR circles) has 
been detected following RAL intensification in 
patients receiving a standard cART suppressive 
regimen (Buzon et al. 2010; Llibre et al. 2012; 
Hatano et al. 2013b), although this observa-
tion was not confirmed by others (Gandhi et al. 
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2012; Gutierrez et al. 2013). This observation 
supports the hypothesis that low-level viral rep-
lication persists in some individuals even after 
long-term cART, and that INSTIs may impact 
on this residual replication. 
Nevertheless, no significant changes in ultra-
sensitive plasma HIV RNA levels were observed 
with RAL intensification (McMahon et al. 2010; 
Gandhi et al. 2012; Gutierrez et al. 2013; Hatano 
et al. 2013b), suggesting that residual viremia 
is prevalently produced by latent stable reser-
voirs, rather than reflecting ongoing active rep-
lication in plasma. In addition, INSTI intensifi-
cation has been associated, although not in all 
studies, with a decrease of CD4 and CD8 T-cell 
activation (Gandhi et al. 2012; Llibre et al. 2012; 
Gutierrez et al. 2013; Hatano et al. 2013b) and 
of coagulation markers levels (D-dimer) (Hata-
no et al. 2013b).
A low-level persistent HIV-1 replication has 
also been detected in CSF in patients with more 
than 10 years of suppressive cART (Dahl-Peter-
son). Around 17% of CSF samples had detect-
able low-level HIV-1 RNA (compared with 57% 
in plasma), and detectable HIV-1 RNA in CSF 
was associated with increased CSF immune 
activation, suggesting that HIV-1 may possi-
bly continue to drive neurological injury even 
during suppressive therapy. 
These findings also indicate that the CNS could 
be a possible reservoir for HIV-1 during sup-
pressive therapy.
However, no effect of INSTI intensification was 
observed on CSF markers of viral replication 
and immune activation. 
Adding RAL to a current suppressive cART reg-
imen did not affect HIV-1 RNA or neopterin 
levels, or intrathecal CD4 and CD8 T-cell activa-
tion (Dahl et al. 2011), similar to what observed 
in intensification studies with non-INSTI an-
tiretroviral drugs (Yilmaz et al. 2010). 
Therefore, although CNS is considered a reser-
voir where antiretroviral drug concentrations 
are generally lower than in blood, it seems not 
to be affected by cART intensification with dif-
ferentially CSF-penetrating drugs (Yilmaz et al. 
2010; Dahl et al. 2011). 
Conclusions
Recent data are accumulating that support the 
neuroprotective potential for INSTIs. While 
CSF penetration of RAL seems to vary among 
subjects, due to the barrier status and, possibly, 
host genetic factors, DTG CSF concentrations 
are more consistently exceeding the desired in-
hibitory HIV-1 concentrations. 
On the other hand, in vitro observations on the 
efficacy of INSTIs in monocytic-macrophage 
cells support their potential to inhibit HIV-1 
replication in CNS macrophages, and confirm 
the efficacy of DTG against RAL-resistant mu-
tants, which may be clinically relevant. 
Although preliminary intensification studies 
with RAL have failed to show an effect on CSF 
markers of replication and immune activation, 
additional clinical and pharmacodynamics 
studies may help understand the full potential 
of INSTIs, including the newer drugs, in inhib-
iting CNS HIV-1 replication and purging the 
CNS reservoir.
BUDGET imPACT mODELS
Davide Croce, Giuliano Rizzardini
Recently, Budget Impact Models (BIM), a tool 
allowing to evaluate the economic impact of 
drug regimens, have captured a lot of atten-
tion. 
The economic crisis and its effects on health 
system funding have made this tool, which 
before was considered as an accessory tool in 
health economic evaluation, a fundamental 
instrument in the evaluation process that pre-
cedes the marketing authorization of pharma-
ceutical products.
FIGURE 3 - Schematic representation of the BIM for 
the introduction of INSTI in clinical practice
M. Andreoni, et al.476
The use of these models is particularly helpful 
for the evaluation of the overall convenience of 
a product and the allocation of the budget re-
sources. 
It is generally accepted that a full economic 
evaluation for a new health system intervention 
requires a cost-efficacy analysis together with a 
budget impact analysis (BIA). 
The aim of BIA is to estimate the economic con-
sequences deriving from the introduction of a 
new health intervention in a specific health sys-
tem or setting (Mauskopf et al. 2007; Sullivan et 
al. 2014). Results of BIM might be of particular 
interest for hospital managers and, in general, 
decision makers of health system balance since 
TABLE 3 - Description of the model.
Entry Specification Notes 
Population 
(HIV treated 
patients)
85500 Population size was estimated as the sum of the total 
number of patients living with HIV in Italy in the 
year 2012 plus the number of newly diagnosed pa-
tients in the year 2013 (3853) according to the Ital-
ian Health Institute (Istituto Superiore di Sanitá, 
ISS). Number of deaths was estimated to be 1% of 
total number of treated patients
Analysis Total HIV-1 positive population, 
stratified in three groups
Stratification was performed as follows: subjects 
undergoing cART for the first time (first regimen), 
experienced patients (i.e. patients who experienced 
virological failure or changed cART regimen due to 
tolerability issues, simplification or other reasons - 
experienced patients harboring virus not resistant 
to INSTIs), and subjects currently in treatment with 
INSTIs (RAL) who experienced virological failure 
due to INSTIs resistance (experienced patients har-
boring virus resistant to INSTIs).
Annual cycle Each year 3853 new infections oc-
cur, 1% of the treated population is 
considered to have resulted in death, 
and 7.82% of patients switches to a 
different therapy*.
Among the patients who change their regimen, 
24,4% belong to the first regimen group, whereas 
65,6% are experienced patients (based on the obser-
vations in a hospital with more than 6000 patients).
Scheme Patients belonging to the first reg-
imen group who switch to a differ-
ent therapy are moved to the group 
of experienced patients not resistant 
to INSTIs unless they received INS-
TIs in the previous year. In the latter 
case they are moved to the group of 
experience patients resistant to INS-
TIs. It is estimated that 3.3% of the 
INSTIs treated population will devel-
op resistance.
Patients belonging to the experienced patients group 
not resistant to INSTIs who switch to a different 
therapy can either remain in the same group (with 
a different regimen) if the failed regimen does not 
include INSTIs, or can be moved to INSTIs expe-
rienced patients group. Patients belonging to the 
INSTIs experienced group cannot switch to other 
groups. 
In case of decease, patients are removed from the 
group
*Based on observations performed in six infectious diseases operative units in the Lombardia Region (Italy) and a total number of 10.600 
patients across a 12 months time window (years 2011-2012).
they provide a useful simulation for balance 
planning. This is one of the main reasons why 
companies selling diagnostic and treatment 
tools provide BIAs as sale support information. 
Moreover, nowadays the main national regu-
latory agencies such as the National Institute 
for Health and Care Excellence (NICE, UK), the 
Pharmaceutical Benefits Advisory Committee, 
as well as the managed care organizations in 
the US require that companies submit the es-
timates of both the cost-efficacy analysis and 
the expected impact of the new interventions 
on the national and local and health budgets in 
order to support the authorization process of a 
new product. 
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TABLE 4 - Cost impact analysis for the reference scenario.
Year 1 Year 2 Year 3 Total
Cost for first regimen patients € 300.603.714 € 323.683.526 € 346.620.493 € 970.907.733
Cost for experienced patients 
not resistant to INSTIs € 691.463.058 € 701.285.752 € 712.586.587 € 2.105.335.396
Cost for experienced patients 
resistant to INSTIs € 30.621.224 € 37.944.464 € 45.419.131 € 113.984.819
Total cost € 1.022.687.995 € 1.062.913.743 € 1.104.626.210 € 3.190.227.948
TABLE 5 - Cost impact analysis for the DTG scenario.
Year 1 Year 2 Year 3 Total
Cost for first regimen patients € 300.974.523 € 323.734.563 € 345.692.341 € 970.401.427
Cost for experienced patients 
not resistant to INSTIs € 692.796.927 € 702.576.612 € 712.876.491 € 2.108.250.029
Cost for experienced patients 
resistant to INSTIs € 29.836.487 € 36.172.603 € 42.447.282 € 108.456.373
Total cost € 1.023.607.937 € 1.062.483.779 € 1.101.016.113 € 3.187.107.829
TABLE 6 - Percent differences between the DTG scenario and the reference scenario.
Year 1 Year 2 Year 3 Total
Cost for first regimen patients 0.1% 0.0% - 0.3% - 0.1%
Cost for experienced patients 
not resistant to INSTIs 0.2% 0.2% 0% 0.1%
Cost for experienced patients 
resistant to INSTIs - 2.6% - 4.7% - 6.5% - 4.9%
Total cost 0.1% 0% - 0.3% - 0.1%
TABLE 7 - Absolute differences between the DTG scenario and the reference scenario.
Year 1 Year 2 Year 3 Total
Cost for first regimen patients € 370.810 € 51.037 - € 928.152 - € 506.306
Cost for experienced patients 
not resistant to INSTIs € 1.333.869 € 30.621.224 € 30.621.224 € 30.621.224
Cost for experienced patients 
resistant to INSTIs - € 784.737 - € 1.771.861 - € 2.971.849 - € 5.528.446
Total cost € 919.942 - € 429.964 - € 3.610.097 - € 3.120.118
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Bim analysis for the iNSTis
The following model investigates the overall 
costs for Italian national health system (Siste-
ma Sanitario Nazionale, SSN) in a scenario in 
which DTG is introduced in clinical practice. 
The model estimates the effects of DTG intro-
duction in terms of health system costs (includ-
ing ARVs, hospitalizations, visits, examinations 
and other concomitant non HAART drugs cost) 
by comparing a standard scenario correspond-
ing to the present situation in Italy with the es-
timated scenario after the introduction of DTG 
in clinical practice.
The model includes a common scenario (year 
0) which is represented by the year 2013, start-
ing from which some hypothesis based on pub-
lic available literature and on the studies for 
the establishment of the diagnostic workup and 
therapeutic options document (PDTA, Lombar-
dia Region) have been formulated. The assump-
tions considered in the model are described in 
Figure 3 and Table 3. 
Scenario: The pharmacological regimens in-
cluded in the model were selected to mirror the 
regimens most frequently used in Italy, based 
on market surveys. The model simulates the 
evolution of the market within a three year time 
frame, changing the market share in presence 
or absence of DTG. The model considers the ex-
pected economic impact of:
1) the introduction of DTG*;
2) the shift to other existing therapies. 
Dosage of DTG in the subgroup of patients who 
are resistant to INSTIs (patients who where 
treated with RAL and developed resistance) is 
estimated to be 50 mg twice a day combined 
with an OBT based on the data available from 
the VIKING-3 study (Castagna et al. 2014) and 
will be compared with a salvage therapy includ-
ing FTC/TDF, etravirine (ETR), DRV, and mar-
aviroc (MVC).
The costs included in the model refer to the 
year 2013. To establish the annual pharmacy 
costs for each treatment, the average annu-
al costs were calculated multiplying monthly 
costs by the number of months corresponding 
to the annual basic need for a patient. Month-
ly drug costs were based on the data reported 
in the Lombardia Region administrative order 
1725 (01/03/2013) (14). 
Previous analysis have shown that the basic 
need per patients corresponds to the number of 
therapeutic units distributed in a time window 
of ten months, due to the incomplete adherence 
to cART and other factors. 
The remaining cost data were calculated based 
on the clinical records taken from (Rizzardini 
et al. 2012), and considering the results of the 
Markov model used for cost-efficiency analysis 
of DTG. The present model compares two sce-
narios differing by the presence or absence of 
DTG with the aim to calculate the differential 
impact and the overall impact of DTG on the 
SSN. 
In order to assess the robustness of the study, a 
sensitivity analysis was carried out on the vari-
ables that determine the cost of treatment and 
the number of patients in therapy: drug cost 
were decrease (-20%), and number of new pa-
tients, percentage of therapy switches and per-
centage of INSTIs resistant patients were allow 
to vary by ±20%.
Table 4 to 7 show the results of the three year 
model projection for the two alternative scenar-
ios. 
As reported in the tables, it is estimated that 
the introduction of DTG in clinical practice will 
lead to a three million euro saving for the SSN 
over a three year time frame.
Estimated total costs calculated in the sensitiv-
ity analysis differed by shortcoming or excess; 
these differences demonstrate the complexity 
and issues currently faced in the pharmaco-
logical management of HIV-1 positive patients 
deriving both from the introduction of generic 
drugs and new molecules and the consequent 
price adjustments and from the financial diffi-
culties of public health institutions.
The results of economic analysis as well as the 
needs of health care operators show significant 
variations due the high dynamism of the cur-
rent situation. 
*It is estimated that naïve patients will be given DTG 
together with a backbone constitute either by FTC/TDF 
(60% of patients) or ABC/3TC (40% of patients) whereas 
in experienced patients, DTG will be used in association 
with an OBT estimated from the data reported in the 
SAILING study (Cahn et al., 2013). In the latter group it 
is estimated that DTG will be used in association with a 
backbone in 40% of cases or with an OBT in the remain-
ing 60% of cases.
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The estimates for the introduction of DTG pre-
dicted by the model show how a drug with a 
well-known efficacy entails an improvement of 
the economic performances for the health sys-
tem despite the elevated cost. However, it must 
be considered that the model is strongly depen-
dent from the assumptions on which is based 
and that the BIM is intended for providing a 
general framework to the health care decision 
makers. 
Future assessment of economic impact for the 
introduction of new drugs will likely need some 
degree of adjustment due to the increasing vari-
ability in the market conditions, which are be-
coming more and more specific between differ-
ent hospitals.
Indeed, from the BIM perspective, co-existence 
of different drug costs prevents the possibili-
ty to a priori and completely define the choice 
with highest economic gain for each health 
care institution. 
Moreover, an additional factor contributing to 
the dynamism of the field of pharmacological 
treatments for HIV-1 infected patients is the in-
troduction of generic drugs, which will become 
available in increasing numbers as patents ex-
pire. Despite the expressions of concern from 
the patient’s associations, generic drugs could 
find large application in HIV-1 treatment de-
pending on drug market regulation and oblig-
atoriness of use. 
This will eventually lead to a decrease in the 
branded drugs price, which will need to be cor-
rected to be competitive with the generic drug. 
This situation will result in a significant in-
crease of public health savings which in turn 
will increase the available funds for more ex-
pensive regimens for the patients who require 
them. 
This virtuous circle needs to be carefully mon-
itored in order to maximize the benefits and 
minimize the “escape from generic drug treat-
ment” which has been previously observed in 
other pharmacological branches. 
CONCLUSiONS
Massimo Andreoni
The development of drugs targeting critical 
steps in the life cycle of HIV-1 has been cen-
tral to treatment success. While RAL is the first 
approved HIV-1 integrase inhibitor, two other 
new INSTIs, DTG and EVG, have been recent-
ly approved The integrase enzyme is essential 
for retroviral replication, and the absence of a 
host-cell equivalent of integrase means that IN-
STI do not interfere with normal cellular pro-
cesses, and therefore have a high therapeutic 
index. INSTIs target the strand transfer step 
of HIV-1 integration; strand transfer integrase 
inhibitors bind in the catalytic core domain of 
the enzyme and compete for binding with host 
DNA. It’s important to note that the stable inte-
gration of the reverse transcribed viral genome 
into host chromatin forms an important point-
of-no- return during HIV infection.
In this review different aspects of the use of IN-
STIs in the prophylaxis and treatment of HIV 
infection are presented.
For both PEP and PrEP, the ideal drug should 
prevent the infection of cells when exposed to 
HIV, or at least abort the virus replication cy-
cle acting before viral integration with cellular 
DNA, providing a theoretical advantage in pre-
venting establishment of HIV infection rather 
than limiting infection. For both PEP and PrEP, 
other drug characteristics critical when select-
ing the appropriate ARVs are safety, tolerability, 
adequate penetration into target tissues, conve-
nient dosing, and few potential drug-drug inter-
actions. Currently available INSTIs have many 
of the characteristics of an ideal agent and are 
currently recommended in first line regimens 
for PEP, while for PrEP, new agents in this class 
are being developed which show promising re-
sults and might represent a new option in HIV-
1 prevention.
Another topic addressed in this review is the 
use of INSTIs in the primary infection treat-
ment. There are not controlled study of this 
scenario, but in several clinical trials a triple 
therapy with INSTIs showed high efficacy in a 
subset of patients with high viral load (above 
100,000 copies/mL) as can be found in prima-
ry infection. Furthermore, the need to quickly 
start the treatment, in absence of data relating 
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to resistance test could be justify the use of IN-
STIs drugs for which the presence of resistance 
mutations are completely exceptional.
The demonstration that INSTIs may extinguish 
the kinetics of viral replication faster and to 
a greater extent justifies the assumption that 
they are more effective than the other antiret-
rovirals of acting on the pathogenetic mecha-
nisms at the basis of the processes of immune 
reconstitution. This is particularly interesting 
in regards to the mechanism of T lymphocyte 
homeostasis, which allows a more complete 
recovery of the immune function. Integrase in-
hibitors may be able to interact significantly on 
two essential mechanisms: immune-activation 
and immune-proliferation, as they are closely 
related to the mechanisms underlying the phe-
nomena of immune exhaustion and the deple-
tion of CD4 T lymphocytes related to HIV-1 
replication. These effects are mirrored by the 
CD4 T lymphocytes gain and the improvement 
in the quality of immune system as seen in both 
naïve and drug-experienced patients.
The three INSTIs recently introduced in clini-
cal practice (RAL, EVG, DTG) proved to be effi-
cient in suppressing viral load in naive patients, 
supporting their use also in patients with high 
levels of HIV-1 replication. Moreover, they were 
well tolerated and showed no relevant pharma-
cological interactions supporting their use in 
patients under treatment for HIV-1 associated 
comorbidities. Taken together, these observa-
tions, promote the use of INSTIs as a compo-
nent of first line cART. 
In recent years, thanks to the improved effica-
cy of current antiretroviral treatment regimens, 
virological failures occur less frequently in clin-
ical practice. However, virological failures may 
sill occur in patients treated with different lines 
of antiretroviral therapy and different combi-
nations of drug classes. Several studies, that 
have analyzed the role of INSTIs in this partic-
ular setting, have demonstrated their effective-
ness after virological failure in patients naive or 
experienced to INSTIs.
However, in patients failing INSTIs, substantial 
differences are found in regard to HIV-1 drug 
resistance. Indeed, because of the low/moder-
ate genetic barrier of RAL and EVG, to avoid 
the resistance development, particular atten-
tion should be deserved on adherence levels 
and on background drugs used in both cART 
- naïve and cART - experienced patients treated 
with these INSTIs. The broad cross-resistance 
profile between RAL and EVG precludes their 
sequential use in individuals failing either of 
them. Differently, in patients who have previ-
ously failed to RAL or EVG, even though the 
presence of Q148 mutation with at least two 
additional INSTI mutations can decrease their 
response rate, DTG bis die administration may 
warrant a residual efficacy. Moreover, the emer-
gence of novel resistance under DTG treatment 
is a rare event that select viruses less prone to 
accumulate further resistance because of their 
low replication capacity, putting DTG as a good 
third drug option in first line treatment. 
INSTIs show a good tolerability and safety pro-
file combined with absence of significant drug 
to drug interactions. However, some precaution 
should be adopted regarding renal function be-
fore prescribing EVG in the fixed formulation 
with COBI. It is recommended to check eGFR at 
baseline when using EVG/COBI/TDF/FTC and 
avoid use of this compound when eGFR is <70 
mL/min. A strictly monitoring of kidney func-
tion with a novel set point of eGFR after one 
month from starting EVG/COBI/TDF/FTC is 
recommended. It is also mandatory monitoring 
tubular function by using urine glucose, urine 
proteins and serum phosphate at baseline and 
then routinely. These procedures are addressed 
to allow the discrimination of an increment 
of eGFR due to impaired creatinine secretion 
or a more concerning onset of proximal renal 
tubular dysfunction due to other drug used in 
the regimen. Nevertheless, a serum creatinine 
change from baseline ≥0.4 mg/dL on consecu-
tive visits is considered an acceptable threshold 
for targeting subjects with potentially serious 
renal adverse events who need an enhanced 
renal monitoring. The same procedure is sug-
gested for DTG only when it is administered in 
association with TDF or other potentially neph-
rotoxic drugs.
Moreover, in recent years, the number of el-
derly persons living with HIV-1 has increased 
as the result of both the availability of effec-
tive antiretroviral therapy, which has reduced 
AIDS-related mortality, and newly diagnosed 
infections occurring in older adults. It is pro-
jected that by 2015, more than half of all HIV- 
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infected people in the United States will be 
over the age of 50. The overlapping epidemics 
between HIV-1 and aging, changes profoundly 
the clinical picture of HIV-1 disease. In this sce-
nario, the availability of the new HIV drug class 
of INSTIs represent a valuable option for the 
treatment of HIV infection, for the unique tol-
erability and potential impact in the capacity to 
contrast mechanisms of residual viral burden 
and secondary reduce the burden of chronic in-
flammation.
New antiretroviral agents like the INSTIs offer 
the opportunity to maintain or promote CD4 T 
cell increase and a prompt and durable HIV-1 
suppression, to treat HIV-1 with a minimal im-
pact on renal function, metabolic disturbances 
and bone metabolism with minimal hepatotox-
icity and a potential for administration in End 
Stage Liver Disease. 
In addition they offer the opportunity of modify 
cART for the duration of anti-HCV therapy to 
circumvent interactions with ribavirin, or the 
new anti HCV drugs and especially with regi-
men including anti HCV protease inhibitors. 
Thus RAL and DTG, may constitute a relevant 
treatment options in the setting of HIV-1 and 
HCV co-infection.
In conclusion, patients with HIV-1 infection 
have several comorbidities requiring multiple 
pharmacotherapies that can increase their risk 
of polypharmacy and related adverse events. 
However, little is known about the impact of ag-
ing on medication use in HIV-1 infected older 
individuals, the potential for interactions with 
cART and administered medications, and the 
impact of this on therapy tolerability and viro-
logical response with aging. 
Reducing pill burden, careful titration of med-
ications, and increasing awareness of common 
drug to drug interactions can prevent co-admin-
istration of potentially harmful combinations 
and reduce unnecessary polypharmacy-related 
adverse events in this population.
Finally, recent data are accumulating that sup-
port the neuroprotective potential for INSTIs. 
While CSF penetration of RAL seems to vary 
among subjects, due to the barrier status and, 
possibly, host genetic factors, DTG CSF concen-
trations are more consistently exceeding the de-
sired inhibitory HIV-1 concentrations. On the 
other hand, in vitro observations on the effica-
cy of INSTIs in monocytic-macrophage cells 
support their potential to inhibit HIV-1 repli-
cation in CNS macrophages, and confirm the 
efficacy of DTG against RAL-resistant mutants, 
which may be clinically relevant. Although pre-
liminary intensification studies with RAL have 
failed to show an effect on CSF markers of 
replication and immune activation, additional 
clinical and pharmacodynamics studies may 
help under- stand the full potential of INSTIs, 
including the newer drugs, in inhibiting CNS 
HIV-1 replication and purging the CNS reser-
voir.
Future assessment of economic impact for the 
introduction of new drugs will likely need some 
degree of adjustment due to the increasing 
variability in the market conditions, which are 
becoming more and more specific between dif-
ferent hospitals. Indeed, from the BIM perspec-
tive, co-existence of different drug costs pre-
vents the possibility to a priori and completely 
define the choice with highest economic gains 
for each health care institution.
In conclusion, given the potency and the rela-
tive safety of the INSTIs in initial trials and in 
clinical practice, today they are considered the 
reference drugs for the treatment of HIV-1 in-
fection.
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3TC: lamivudine; ABC: abacavir; ARV: an-
tiretroviral; ATZ: atazanavir; ATZ/r: ritonavir 
boosted atazanavir; BIA: budget impact anal-
ysis, BIM: budget impact models; cART: com-
bination antiretroviral therapy; COBI: cobici-
stat; DRV: darunavir; DRV/r: ritonavir boosted 
darunavir; DTG: dolutegravir; EFV: efavirenze; 
EVG: elvitegravir; ETR: etravirine; FTC: emtric-
itabine; LPV: lopinavir; INSTI: integrase strand 
transfer inhibitors; MVC: maraviroc; NNRTI: 
non nucleoside reverse transcriptase inhibi-
tors; NRTI: nucleoside reverse transcriptase in-
hbitors; OBT: optimal backbone therapy; PEP: 
post-exposure prophylaxis; PrEP: pre-exposure 
prophylaxis; PI: protease inhibitors; SSN: Siste-
ma Sanitario Nazionale (National Health Sys-
tem); TDF: tenofovir disoproxil fumarate.
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